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G protein-coupled receptors (GPCRs) comprise a large family of related seventransmembrane-helical membrane proteins that bind to specific extracellular ligands, such
as hormones or neuromodulators. The active receptor-ligand complex then engages with
a heterotrimeric G protein on the cytoplasmic surface of the plasma membrane to
facilitate a change in the concentration of an intracellular second messenger, such as
cAMP. A number of non-canonical signaling pathways, such as β-arrestin-mediated
signaling, also exist for many, if not all, GPCRs. Receptor signaling is attenuated by
phosphorylation and receptor internalization. Recent advances in structural studies of
GPCRs have revealed high-resolution structures of both inactive and active receptors in
complex with various ligands. Endogenous ligands, drugs and the membrane
environment, and even oligomerization can affect receptor signaling efficacy, but the
mechanistic details underlying these allosteric effects are poorly characterized. To study
allosterism of a ligand-receptor complex in a bilayer requires at least partial enrichment
or isolation of the basic signaling unit. Many studies have employed biochemical

purification and reconstitution strategies, but GPCRs are inherently unstable when
extracted from native membranes so conditions must be carefully selected to preserve
receptor integrity. To monitor the functional state of GPCRs during purification and
reconstitution, a novel homogeneous time-resolved fluorescence resonance energy
transfer (FRET)-based analytical assay was developed. To enable the assay, a novel
bioconjugation method was invented to prepare microgram quantities of monoclonal
antibodies labeled with long-lived lanthanide fluorophores. As a proof-of-concept, the
folding and stability of human C-C chemokine receptor 5 (CCR5), the primary coreceptor for HIV-1 cellular entry, was studied. The assay enabled high-throughput
detection of femtomole quantities of CCR5. Thermal denaturation measurements
demonstrated that small molecule antagonists substantially stabilize CCR5 and also
revealed that the ligands induce distinct receptor conformations, consistent with the
hypothesis that GPCRs access numerous conformations during signal transduction rather
than operating as a binary active-inactive switch. In addition, high-throughput stability
screens led directly to the identification of CCR5 mutants that should be sufficiently
stable for crystallization and lead to a high-resolution structure of CCR5, which would
significantly advance understanding of the structural basis of HIV entry. The FRETbased assay was also applied to devise and optimize a protocol to incorporate CCR5 into
an artificial membrane scaffold called nanoscale apolipoprotein bound bilayers (NABBs).
CCR5 was shown to retain proper folding in NABBs and proof-of-concept fluorescence
correlation spectroscopy (FCS) experiments were carried out to characterize these
structures. Novel FCS standard reagents were developed to facilitate these measurements.
The biochemical and analytical approaches reported may be adapted to prepare stable,

functional samples of other GPCRs for structural and dynamic studies of receptor
allostery. GPCRs are known to form dimers and higher-order oligomers, and despite a
growing body of evidence that these complexes are functionally important, the structural
basis of receptor-receptor interactions remains unknown. To address this problem, a
potential dimerization interface of the prototypical GPCR, rhodopsin, was analyzed using
a proteomics approach involving chemical crosslinking and liquid chromatography-mass
spectrometry. The strategy was devised so that rhodopsin could be probed in the unique
native environment of the rod cell disk membrane. Crosslinking results supported a
model of rhodopsin dimerization involving contacts in transmembrane helix 1 and an
amphipathic cytoplasmic helix at the carboxyl-terminal tail of the receptor. This novel
interface is postulated to be relevant for understanding GPCR oligomerization in general.
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Chapter One: Introduction	
  

1.1

G Protein-Coupled Receptors in Cell Signaling

G protein-coupled receptors (GPCRs) constitute the largest superfamily of
membrane proteins in the human genome, with at least 800 members (Fredriksson and
Schioth, 2005). These signal transducers respond to a remarkably broad array of ligands,
including photons, ions, small molecules, peptides, and small proteins. Conformational
changes associated with receptor activation propagate the signal across the membrane to
elicit intracellular responses. GPCRs are involved in processes as diverse as the senses of
vision, smell, and taste, as well as neurotransmission, immune, and hormone responses.
They thus represent a core component of vertebrate physiology. GPCRs exhibit a
common topology of seven hydrophobic α-helices, an extracellular N-terminus, and an
intracellular C-terminus. The International Union of Pharmacology has subdivided the
GPCR superfamily into five classes, with the visual pigment rhodopsin as the prototype
of class 1, the largest (also known as family A) (Foord et al., 2005). Most family A
receptors have short N-termini compared with other families and interact with ligands
primarily through contacts in the transmembrane (TM) and extracellular (EC) loop
regions (Bockaert and Pin, 1999). Structural features common to many family A
receptors include a disulfide bridge between cysteine residues in the EC1 and EC2 loops
and cysteine palmitoylations at the C-terminus. A short amphipathic eighth helix has also
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been observed in high-resolution crystal structures, among them the very first snapshot of
rhodopsin (Palczewski et al., 2000). In addition, there are several highly conserved
sequence regions, most prominently the E(D)RY, NPxxY(x)5,6F, and CWxP motifs.
These residues appear to be involved in key hydrogen bond networks that stabilize
inactive and active conformations (Hofmann et al., 2009).
The classical, and eponymous, GPCR signaling pathway involves the activation
of heterotrimeric G proteins (Gαβγ). Extracellular ligand binding stabilizes a G proteincompetent receptor conformation (Nygaard et al., 2009). The activated receptor catalyzes
GDPàGTP exchange in the Gα subunit, which then dissociates from the receptor and
Gβγ subunits. Gα and Gβγ can proceed to interact with a number of effector proteins and
second messengers depending on the subtype involved and the cellular context (Figure 11) (Dorsam and Gutkind, 2007). The four Gα subfamilies – Gαs, Gαi,Gαq, and Gα12 –
regulate the activity of different pathways (Sprang et al., 2007). Gαs and Gαi primarily
stimulate and inhibit adenylyl cyclase, respectively. Gαq binds and activates
phospholipase C. Gα12 mainly acts on guanine nucleotide exchange factors. Interestingly,
many GPCRs signal through more than one type, possibly because different ligands
stabilize distinct active states (Kenakin, 2003). Gβγ heterodimers activate
phospholipases, ion channels, and lipid kinases, among other molecules. Hydrolysis of
GTP to GDP, either spontaneously or via catalysis by GTPase-activating proteins, leads
to reassociation of the heterotrimer and completion of the G protein cycle. Receptor
desensitization occurs through phosphorylation by GPCR kinases (GRKs) and
subsequent β-arrestin binding (Krupnick and Benovic, 1998). Many GPCRs are then
internalized via clathrin-mediated endocytosis, from which they may be recycled,
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REVIEWS
Biogenic amines
Amino acids and ions
Noradrenaline, dopamine, Glutamate, calcium,
5-HT, histamine,
GABA
acetylcholine

Lipids
LPA, S1P, prostaglandins, leukotrienes
Peptides and proteins
Chemokines, angiotensin, thrombin, bombesin, endothelin, bradykinin
Others
Light, odorants, nucleotides

α

γ

β

β

PI3Kγ
PLCβ
Ion channels

γ

GRK
PKA

αs

αq

αi
GTP

Biological responses
Proliferation, cell survival,
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ECM degradation, angiogenesis,
metastasis, cancer

β1–5
γ1–14

GTP

α12
GTP

GTP

Subtype
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GαsXL
Gαsolf

Gαi1-3
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Gαz, Gαgust

Gαq, Gα14
Gα11, Gα15/16

Gα12
Gα13

Effector
Adenylyl cyclase
Axin
↑(cAMP)
PKA

Adenylyl cyclase
Phosphodiesterases
Phospholipases
↓(cAMP)

PLCβ
Lbc
↑(Ca2+)
PKC
Rho

P115–RhoGEF
LARG
PDZ–RhoGEF
AKAP–Lbc
Rho

Gene expression

Transcription
factors

Figure 1 | Diversity of G-protein-coupled receptor signalling. Various ligands use G-protein-coupled receptors
(GPCRs) to stimulate membrane, cytoplasmic and nuclear targets. GPCRs interact with heterotrimeric G proteins
composed of α, β and γ subunits that are GDP bound in the resting state. Agonist binding triggers a conformational
change in the receptor, which catalyses the dissociation of GDP from the α subunit followed by GTP-binding to Gα and
Figure
1-1. Schematic
of canonical
GPCR
through
G proteins.
1
. The α subunits
of Gsignaling
proteins are divided
into four
subfamilies: Receptor
Gαs, Gαi, Gαq and
the dissociation
of Gα from Gβγ subunits
Gα12, and a single GPCR can couple to either one or more families of Gα proteins. Each G protein activates several
2
downstream effectors
. Typically
adenylyl cyclase
and increases
levels
of cyclic AMPexchange
(cAMP), whereas
i
activation
in response
toGαans stimulates
extracellular
stimulus
leads to
nucleotide
in Gα
a Gα
inhibits adenylyl cyclase and lowers cAMP levels, and members of the Gαq family bind to and activate phospholipase C
(PLC), which cleaves phosphatidylinositol bisphosphate (PIP2) into diacylglycerol and inositol triphosphate (IP3). The Gβ
subunits and
Gγ subunits
function
as a dimer to
activate many
molecules,
including phospholipases,
ion
subunit.
Gα
and Gβγ
dissociate,
resulting
in signalling
activation
and regulation
of downstream
channels and lipid kinases. Besides the regulation of these classical second-messenger generating systems, Gβγ subunits
and Gα subunits such as Gα12 and Gαq can also control the activity of key intracellular signal-transducing molecules,
signaling
pathways
that
vary
byRas
subtype.
Theseandnetworks
many cellular
functions
including small
GTP-binding
proteins
of the
and Rho families
members of control
the mitogen-activated
protein kinase
(MAPK) family of serine-threonine kinases, including extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase
(JNK), p38 and ERK5, through an intricate network of signalling events that has yet to be fully elucidated1,4,6. Ultimately, the
and
irregular
can cause
disease states.signalling
Figurenetworks
taken control
from many
(Dorsam
Gutkind,
integration
of the activity
functional activity
of the G-protein-regulated
cellularand
functions,
and
the aberrant activity of G proteins and their downstream target molecules can contribute to cancer progression and
metastasis. 5-HT, 5-hydroxytryptamine; ECM, extracellular matrix; GABA, gamma-aminobutyric acid; GEF, guanine
2007).
nucleotide exchange factor; GRK, G protein receptor kinase; LPA, lysophosphatidic acid; PI3K, phophatidylinositol 3kninase; PKA and PKC, protein kinase A and C; S1P sphingosine-1-phosphate.

Orphan receptor
A general designation for
GPCRs for which ligands have

a transcriptional co-activator, FHL2 (four and a half LIM
domains 2), which binds AR28, and by stimulating protein
kinase N (PKN), which phosphorylates AR directly. Rho
thereby increases the effect of otherwise weakly active
circulating androgens, and can even convert clinical AR
antagonists into agonists29. Therefore, the stimulation
of Rho can greatly increase the response of AR to male
hormones and even switch the pharmacological profile
of AR, thereby providing a mechanism by which GPCRs
can contribute to androgen-independent prostate cancer

GPCRs link inflammation to cancer
Prostaglandins are a product of the cyclooxygenases
COX1 and COX2, and their pro-inflammatory functions are initiated after the binding of prostaglandins to
their cognate GPCRs that are expressed in many cells.
Treatment with non-steroidal anti-inflammatory drugs
3(NSAIDs) that inhibit COX1 and COX2 can reduce the
risk and incidence of many types of cancer. Indeed,
COX2 overexpression and chronic inflammation are
now believed to have an important role in tumour

degraded, or perhaps even continue signaling through alternative pathways (Scita and Di
Fiore, 2010).
GPCRs form many complexes in addition to the canonical ternary “signalosome”
comprising ligand, receptor, and G protein. Following GRK-mediated seryl/threonyl
phosphorylation, binding of β-arrestins can facilitate scaffolding and signaling though
MAP kinase pathways (Shenoy and Lefkowitz, 2011). It is possible that some ligands
stabilize a conformation that favors binding and signaling through arrestins rather than G
proteins. GPCRs are also known to form dimers and higher-order oligomers, like many
other membrane receptors. Though the functional implications of these complexes remain
somewhat murky, heterodimerization has proven key in certain cellular trafficking and
signaling contexts (Bouvier, 2001). Clearly, the structure, conformational dynamics, and
composition of GPCRs and their complexes bear tremendous significance for our
understanding of cell biology and physiology.

1.2

GPCRs in Disease and Drug Development

Given their expression in many cell types, functional importance, and plasma
membrane localization, one would expect GPCRs to play major roles in clinical
medicine. Indeed, GPCRs have been implicated in the molecular pathophysiology of a
number of diseases (Insel et al., 2007). There are some examples of rare monogenic
diseases involving GPCRs, perhaps most notably in rhodopsin, where certain mutations
lead to retinitis pigmentosa, a leading cause of blindness (Mendes et al., 2005). GPCRs
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are also the target of antibody products in autoimmune diseases such as Graves’ disease,
in which the thyroid-stimulating hormone receptor is chronically stimulated (Schott et al.,
2005). GPCR genes also display a large number of polymorphisms; these may lead to
altered receptor expression, targeting, and signaling properties that affect physiology. A
famous example involves the chemokine receptor CCR5, a primary co-receptor for the
HIV virus. Approximately 1% of the human Caucasian population carries a 32-base pair
deletion in the EC2 loop. This CCR5Δ32 variant does not traffic to the cell membrane,
conferring almost complete resistance to HIV-1 infection (Samson et al., 1996).
In addition to their direct involvement in disease states, GPCRs have been the
most fruitful drug targets to date. An estimated 30-50% of marketed drugs act either
directly or indirectly on GPCRs, including 5 of the top 15 generic drugs and 7 of the top
15 prescription drugs (Salon et al., 2011). Some especially notable examples include: βadrenergic receptor antagonists (“beta-blockers”) to treat heart disease and hypertension,
dopamine receptor antagonists (schizophrenia) and agonists (Parkinson’s), and
antihistamines (Lagerstrom and Schioth, 2008). Despite these successes, at present only
~20 of the aforementioned >800 receptors are targets of clinically approved drugs
(Overington et al., 2006). Of course, this does not imply that the rest are “undruggable.”
Rather, it reflects the inherent difficulties of drug development, and a tendency to use old
drugs as templates for new ones. This untapped therapeutic potential demands a greater
fundamental understanding of GPCR structure and allostery, as well as the development
of new high-throughput screening tools and efforts to “deorphanize” receptors for which
endogenous ligands remain unknown.

5

1.3

GPCR Structural Biology

The past few years have witnessed remarkable advances in the structural biology
of GPCRs. The first crystal structure of rhodopsin was reported in 2000 (Palczewski et
al., 2000), but it took until 2007 before another receptor structure, that of β2-adrenergic
receptor, was solved (Cherezov et al., 2007; Rasmussen et al., 2007). These structures
captured inactive states, with the receptor bound to the inverse agonist carazolol. Since
then, a number of other GPCRs have been crystallized in antagonist- or inverse agonistbound forms: β1-adrenergic receptor (Warne et al., 2008), A2A adenosine receptor
(Jaakola et al., 2008), M2 muscarinic receptor (Haga et al., 2012), histamine H1 receptor
(Shimamura et al., 2011), chemokine receptor CXCR4 (Wu et al., 2010), dopamine D3
receptor (Chien et al., 2010), and κ- (Wu et al., 2012) and µ-opioid (Manglik et al., 2012)
receptors, among others. These receptors were stabilized by ligand binding and a number
of biochemical methods, including truncations, protein fusions, binding of Fab fragments,
and stabilizing mutations. The overall similarity in architecture between receptors is
striking; among the earliest structures, the root mean squared deviations of the
transmembrane domains was less than 3 Å (Rosenbaum et al., 2009). Unsurprisingly, the
intracellular regions, where GPCRs couple to comparably few binding partners, are
especially similar. Subtle differences do exist – such as the presence or absence of an
“ionic lock” between highly conserved residues in TM3 and TM6 and a short α-helix in
the I2 loop – but overall the structures support a conserved mechanism of activation.
Conversely, larger differences are apparent in the extracellular loops and ligand-binding
regions. While the rhodopsin structure reveals a β-sheet in E2 that covers the 11-cis-
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retinal chromophore, other receptors have E2 secondary structures that expose the ligandbinding cavity to solvent. This makes sense: most GPCRs reversibly bind diffusible
ligands, and access to the binding pocket is necessary if energetically favorable
interactions are to form. Another interesting point of variation concerns the ligand
binding orientation. The β-receptor and rhodopsin ligands run roughly parallel to the
bilayer plane, but the A2A receptor ligand tilts closer to perpendicular resulting in
substantially different contacts. This suggests that GPCRs can be activated through a
variety of interactions in the extracellular loops and transmembrane regions.
Stabilizing GPCRs for crystallization in an active state has proven a trickier task,
which was to be expected given the associated increased conformational flexibility.
Rhodopsin has been crystallized in a G protein-interacting form (Scheerer et al., 2008)
and active Meta II state (Choe et al., 2011). The β2 receptor was stabilized in an active
state by a camelid antibody fragment (nanobody) with G protein-like activity toward the
receptor (Rasmussen et al., 2011a). The β1 (Warne et al., 2011), A2A adenosine (Lebon et
al., 2011), and neurotensin (White et al., 2012) receptors have now also been crystallized
in agonist-bound forms. These structures exhibit common differences compared to the
earlier inactive structures, with a contraction of the ligand binding pocket and rotation of
the cytoplasmic end of H6. The most technically impressive structure to date is the first
high-resolution image of the receptor-G protein complex: β2-adrenergic receptor with Gs
in its nucleotide-free form (Rasmussen et al., 2011b). Both nanobody binding and T4
lysozyme fusion were necessary to obtain a stable complex. The resulting structure
reveals that the β and γ subunits of Gs barely make any contact with the receptor,
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lular region is indirectly tethered to the well-packed soluble com- consistent with high structural homology
ponents by the amino-terminal fusion to T4 lysozyme (Fig. 2a). pocket.
Given the flexible and dynamic nature of GPCRs, the absence of
The active state of the b2AR is stabilized
stabilizing packing interactions may lead to structural heterogeneity with GasRas (Fig. 4). There are no direct i
in the extracellular half of the receptor and, consequently, to the limited subunits. The total buried surface of the
quality of the electron density maps. However, the overall structure of 2,576 Å2 (1,300 Å2 for GasRas and 1,276 Å
the b2AR in the T4L–b2AR–Gs complex is very similar to our recent face is formed by ICL2, TM5 and TM6 of
active-state structure of b2AR stabilized by a G protein mimetic nano- the aN–b1 junction, the top of the b3-st
body (Nb80)12. In the b2AR–Nb80 crystal, each receptor molecule has GasRas (see Supplementary Table 1 for sp
extensive packing interactions with adjacent receptors and the quality of the b2AR sequences involved in this inter
of the electron density maps for the agonist-bound b2AR in this have a role in G protein coupling; however,
complex is remarkably good for a 3.5 Å structure. Therefore, the sequence for Gs-coupling specificity when
b2AR–Nb80 structure allows us to confidently model BI-167107 here, with other GPCRs. Perhaps this is not surp
and provide a more reliable view of the conformational rearrange- b2AR also couples to Gi and that many G
ments of amino acids around the ligand-binding8pocket and between one G protein isoform. Of the 21 amino aci
of the b2AR, only five are identical between
the ligand-binding pocket and the Gs-coupling interface12.
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and that the α subunit C-terminus binds in an open crevice formed by H6 motion (Figure
1-2). Though this structure marked an important milestone in the field, it is possible or
perhaps likely that the considerable structural changes required to stabilize the complex
resulted in a somewhat contrived system that deviates from the true physiological form.
This is a common tradeoff, and achieving stability represents a core issue in GPCR
structural biology. Analytical methods to assess receptor stability for crystallization and
other assays are discussed in detail in Chapter 3.
Regardless of progress in structural biology, crystal structures are unlikely to
reveal the basis of full versus partial agonism, or how receptor engagement facilitates Gα
nucleotide exchange (Schwartz and Sakmar, 2011). While additional crystal structures of
different GPCRs and complexes with G proteins are needed, complementary biophysical
approaches will also be necessary to grasp the signal transduction process.

1.4

GPCR Allostery and Dynamics

GPCRs may be best thought of as exquisite allosteric machines, with many
accessible energetic states that are promoted by extracellular or intracellular binding
partners. The classical signaling paradigm considers the receptor as a binary on-off
switch, but a wealth of biochemical, biophysical, and pharmacological data has
challenged this simple model (Deupi and Kobilka, 2007; Huber and Sakmar, 2011).
Fluorescence lifetime spectroscopy experiments have revealed numerous receptor
substates (Ghanouni et al., 2001). Some sets of agonists exhibit different potency rank
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orders depending on the G protein stoichiometry, even in the same receptor system. This
behavior cannot be explained by a single active state (Kenakin, 2003). There are even
examples of agonists that function as partial agonists for a receptor and inverse agonists
for the same receptor in a constitutively active state, again suggesting a range of
conformations (Kenakin, 1997). Further, ligands can cause receptors to form oligomers,
bind adaptor proteins, and internalize, among other activity (Brady and Limbird, 2002).
Clearly, GPCR signaling encompasses far more complex behaviors than a one- or
even two-dimensional model might encapsulate. These qualities are not merely of
academic interest, either. Given the massive role that GPCRs play in drug discovery, one
can envision a therapeutic landscape in which molecules selectively promote desirable
actions while avoiding others. For example, a CCR5 agonist that promotes internalization
but not G protein signaling might prevent viral resistance without inflammatory side
effects. How can the underlying conformational complexity be unveiled? Cell-based
signaling assays are an indirect readout of activity downstream of the receptor. Despite
the remarkable advances in GPCR structural biology, and the value of visualizing
receptor conformations at high resolution, it seems extremely impractical to crystallize
every ligand-receptor-G protein (or GRK, or arrestin, or oligomer) complex of interest.
Even if one could, the structures would reveal little about their thermodynamic stability
and the pathway of interconversion between states.
Purification and reconstitution of receptors in membrane bilayers, along with
ligands and binding partners of interest, enables the experimenter to probe structurefunction relationships in a defined system. Though in vitro experiments cannot replicate
the full suite of roles GPCRs play in cell biology, they are well suited to determine the
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sequence and kinetics of receptor binding events upon ligand stimulation. Fluorescence
methods – including total internal reflection microscopy (TIRF) and fluorescence
correlation spectroscopy (FCS) – are especially powerful ways to observe receptors in
action. These approaches present considerable technical difficulties, however. Purified
receptors are inherently very unstable, assessing sample quality is not straightforward,
and labeling methods present a tradeoff between ease and sample perturbation. New tools
must be developed to facilitate these kinds of experiments. The potential fruits of these
efforts – observing the composition and evolution of signaling complexes over time at a
single molecule level – provide ample motivation. Toward this goal, reconstitution of
GPCRs into membrane nanoparticles and the development of FCS methods are discussed
in Chapter 4.

1.5

Rhodopsin: A Prototypical GPCR

Rhodopsin, the visual pigment in rod photoreceptor cells, has proven to be an
excellent model GPCR. Rhodopsin possesses several qualities that have made it
particularly amenable to experimental study. It can be purified in large quantities from
bovine retinae, is unusually stable in its dark state, and is quickly and efficiently activated
upon exposure to light (Menon et al., 2001). In the dark, rhodopsin is covalently bound to
its chromophore, 11-cis-retinal, via a Schiff base at Lys296. In this state, the
chromophore acts as a potent inverse agonist; rhodopsin displays no basal activity, unlike
other GPCRs. Absorption of a photon causes retinal isomerization and a propagation of
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conformational changes that result in a G protein-competent state, Meta II, which
catalyzes nucleotide exchange in transducin (Figure 1-3) (Hofmann et al., 2009).
Transducin activates cGMP phosphodiesterase, which leads to closing of cGMP-gated
ion channels in the rod cell plasma membrane and hyperpolarization of the photoreceptor
cell. This remarkably sensitive light response system is capable of single photon
detection and operates with extremely fast kinetics and high gain. The chromophore
Schiff base hydrolyzes within minutes, leaving the apoprotein opsin. Fresh, metabolically
provided 11-cis-retinal then binds the receptor to complete the photocycle.
Though rhodopsin is a highly specialized GPCR with unique characteristics, its
overall structural features and activation pathway is generally representative of the largest
family of GPCRs, which bears its name. In addition to its chromophore, rhodopsin
contains a disulfide bond between the E1 and E2 loops (Cys110-Cys187), acetylation
(Met1), N-linked glycosylations (Asn2 and Asn15), and C-terminal palmitoylations
(Cys322 and Cys323) (Palczewski, 2006). Numerous crystal structures of rhodopsin have
now been reported, including the dark state (Okada et al., 2004), Meta II state (Choe et
al., 2011), and opsin bound to a Gα-derived peptide (Scheerer et al., 2008). In the dark
state, H3 is tethered to H6 through a hydrogen bond network that might be a common
GPCR feature (Hofmann et al., 2009). In the active states, H6 is rotated outward to form
a cytoplasmic crevice for G protein binding, confirming an activation model that was
hypothesized in earlier cross-linking studies (Farrens et al., 1996; Sheikh et al., 1996). A
more recent Fourier-transform infrared spectroscopy report showed that this helical
rearrangement begins in the Meta I state, even while the G protein-binding pocket
remains inaccessible (Ye et al., 2010).
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microseconds, the activation remains near the retinal binding pocket
and only minor structural changes occur in the more distant parts of
the protein [51,52,101]. With the formation of Meta I, the activation
path reaches the level of the Meta intermediates. The spectrally
identical Meta II substates Meta IIa, Meta IIb and Meta IIbH+
sequentially develop from one another until an equilibrium between
all the states is reached after a few milliseconds. At physiological pH
and temperature, Meta IIbH+ accumulates in the reaction sequence
[69]. In the course of the Meta conversions, deprotonation of the
retinal Schiff base and protonation of Glu1133.22 of its complex
counterion (step 1), motion of TM6 (step 2) and proton uptake to the
TM3–TM6 ionic lock microdomain (step 3) occur sequentially. Thus,

magnitude less active towards the G protein than Meta II [12,13], but
lower pH enhances its activity [62,102].
The residual activity of opsin can be explained by an active (Ops*)
conformation in pH-dependent equilibrium with inactive opsin
[49,62,103]. The free energy gap between Meta II and Ops* can be
estimated from the apparent pKa at which the respective species forms.
Meta II appears at an apparent pKa of >7.5, whereas the pKa for Ops*
formation is 4.1 [49,69]. The difference in pKa equates to a difference in
free energy of approximately 5 kcal/mol, which can be assigned to the
stabilizing effect of the all-trans-retinal agonist present in Meta II but not
in Ops*. Consistently, Meta II and Ops* exhibit a similar difference in
their pH-rate profiles for G protein activation [62,102–104].

Figure I. Rhodopsin and light-activated photoproducts. The early photoproducts of rhodopsin related to the reactions of its photosensory core are underlined in red and
the late Meta intermediates in blue.

Figure 1-3. Schematic of the rhodopsin photocycle. Photoactivation causes retinal
isomerization, and the receptor proceeds through a fast series of photointermediates
before arriving at the active Meta II state within milliseconds. The retinylidene Schiff
base hydrolyzes within minutes and all-trans-retinal diffuses out of the protein.
Metabolically supplied 11-cis-retinal regenerates dark state rhodopsin. Figure taken from
(Hofmann et al., 2009).
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Rhodopsin has been visualized in its native membranes by atomic force
microscopy (AFM) and transmission electron microscopy (TEM) (Fotiadis et al., 2003;
Liang et al., 2003). These images revealed neatly arranged rows of dimers that interactto
form higher-order structures. Though it is possible that this arrangement is an artifact of
the experimental conditions, the isolated discs were shown to function normally. The
extremely high packing density of rhodopsin (30,000-55,000/µm2 in the AFM images) far
exceeds that of other GPCRs, but a large amount of evidence has demonstrated that other
GPCRs dimerize as well (Palczewski, 2010). Despite the recent advances in GPCR
structural biology, the precise structural basis of dimerization for rhodopsin and other
GPCRs remains controversial. The close homology of family A receptors suggests modes
of interaction may be highly similar, so the question of rhodopsin dimerization carries
broad significance. Complementary biochemical, proteomics, and computational methods
were applied to this problem. The results are presented and discussed in Chapter 5.
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1.6

Chemokine Receptor CCR5

Unlike rhodopsin, most GPCRs reversibly bind diffusible ligands, adding another
layer to the signalosome. Chemokine receptors represent one of these subfamilies.
Chemokines are secreted molecules that facilitate directed cell migration in immune
responses. These small proteins are thought to bind adhesion molecules called
glycosaminoglycans at an inflammation site, providing a local concentration of
chemoattractants for target cells expressing chemokine receptors (Springer, 1994).
Roughly 50 chemokines and 20 receptors have been identified, and they are classified on
the basis of cysteine residue patterning in the ligands (e.g. CC, CXC, etc.). These
signaling networks exhibit significant promiscuity in biochemical binding assays: many
chemokines bind multiple receptors and vice versa, though this apparent redundancy may
be partially mitigated by spatiotemporal resolution in vivo. Nonetheless, the system is
remarkably complex.
Chemokine receptors are involved in a large number of pathophysiologies,
including autoimmune disorders, pulmonary disease, vascular disease, and cancer (Allen
et al., 2007). In addition, as mentioned above, CCR5 (along with CXCR4) is a primary
co-receptor for HIV-1 (Lusso, 2006). The native ligands of CCR5 – RANTES, MIP-1α,
and MIP-1β – are potent inhibitors of HIV infection, likely because they promote
receptor internalization. Small molecules and antibodies targeting CCR5 have also been
developed to block viral entry by preventing gp120 binding to the co-receptor (Horuk,
2009). CCR5 has thus attracted much attention, and an understanding of its structure and
functional properties has significant clinical relevance.
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Ligand binding to chemokine receptors appears to involve multiple regions of the
receptor. One model for chemokine binding to CCR5 posits that the globular body of the
chemokines binds at the receptor N-terminus and extracellular loops, while the
chemokine N-terminus is directed into the helical bundle (Blanpain et al., 1999). It has
also been shown that tyrosine sulfation of CCR5 at multiple N-terminal sites contributes
to both binding of native ligand and HIV entry. The receptor is glycosylated primarily at
Ser6 (Farzan et al., 1999), and palmitoylation at C-terminal cysteine residues is important
for trafficking and stability, much like in rhodopsin (Percherancier et al., 2001). While
the crystal structure of CXCR4 has been reported (Wu et al., 2010), the structure of
CCR5 has not yet been solved. In fact, despite its considerable importance in
immunology and disease, relatively few studies with purified CCR5 have been reported
to date. This receptor is thus an excellent candidate for studies aiming to understand
receptor activation, functional selectivity, and allosteric modulation by native ligands and
drugs.
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Chapter Two: Materials and Methods

2.1

Reagents and Buffers

2.1.1 Cells, Plasmids, and Chemicals
HEK-293T cells were obtained from the American Type Culture Collection (Manassas,
VA). Mammalian expression vectors and transfection reagents were obtained from
Invitrogen (Carlsbad, CA). Restriction enzymes were obtained from New England
Biolabs (Ibswich, MA). Chemicals were obtained from Sigma-Aldrich (St. Louis, MO)
except where noted. Lipids were obtained from Avanti Polar Lipids (Alabaster, AL),
except cholesterol, which was obtained from Sigma-Aldrich. Detergents were obtained
from Anatrace, Inc. (Maumee, OH). Homogeneous time-resolved fluorescence (HTRF)
reagents were obtained from Cisbio (Bedford, MA).

2.1.2 Buffers

Buffer N: 20 mM Tris-HCl (pH 7.0), 0.1 M (NH4)2SO4, 10% (v/v) glycerol,
0.07% cholesteryl hemisuccinate (CHS), 0.018% 1,2-dioleoyl-sn-glycero-3phosphocholine (DOPC), 0.008% 1,2-dioleoyl-sn-glycero-3-phospho--serine
(DOPS), 0.33% n-dodecyl β-D-maltoside (DM), and 0.33% 3-[(3cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS)
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Buffer E1: Buffer N supplemented with 400 µM 1D5-nonapeptide corresponding
to the engineered C-terminal receptor epitope C9, TETSQVAPA
Buffer S: 20 mM Tris-HCl (pH 7.0), 100 mM (NH4)2SO4, and 10% (v/v)
glycerol
Buffer C: 100 mM phosphate and 150 mM NaCl (pH 7.2)
Buffer P: 100 mM phosphate and 150 mM NaCl (pH 7.5)
Buffer E2: Buffer P supplemented with 200 mM imidazole
Buffer G: 100 mM phosphate, 150 mM NaCl, and 0.5 mg/mL BSA (pH 7.0)
Zap1 purification buffers:
Buffer HZ: 40 mM Tris (pH 8.0), 300 mM NaCl, 5 mM 2mercaptoethanol, complete ethylenediaminetetraacetic acid (EDTA)-free
protease inhibitor tablet, 2 mM PMSF
Buffer TZ: 25 mM Tris (pH 8.0), 300 mM NaCl, 20 mM imidazole, 0.5
mM TCEP, 1% (v/v) Triton X-100
Buffer CZ: 25 mM Tris (pH 8.0), 300 mM NaCl, 20 mM imidazole, 0.5
mM TCEP, 20 mM sodium cholate
Buffer AZ: 25 mM Tris (pH 8.0), 300 mM NaCl, 20 mM imidazole, 0.5
mM TCEP
Buffer BZ: 25 mM Tris (pH 8.0), 300 mM NaCl, 500 mM imidazole, 0.5
mM TCEP
Buffer GZ: 10 mM Tris (pH 8.0), 150 mM NaCl, 0.5 mM TCEP
Buffer EL: Dulbecco’s PBS (pH 7.2) with 5 mg/mL BSA
Buffer CF: 1X Hank’s Balanced Salt Solution (Gibco), 20 mM HEPES (pH 7.4),
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2 mg/mL BSA
Buffer RB: 50 mM HEPES (pH 7.4), 1 mM CaCl2, 5 mM MgCl2, and 5 mg/mL
BSA
Buffer T: 10 mM Tris-HCl (pH 7.5) with 5 mM CaCl2

2.1.3 Instruments
All UV-Vis spectra were acquired on a Perkin-Elmer Lambda 800 Ultraviolet-visible
spectrophotometer. All FPLC purifications were carried out on an Äkta Explorer system
(GE).

2.2

Preparation of Lipids

Lipids were dissolved in chloroform at a concentration of approximately 100 mg/mL in
glass round-bottom flasks. The solvent was evaporated under a gentle stream of dry argon
while the flask was rotated, forming a thin lipid film. The lipids were redissolved in
dichloromethane, and the procedure was repeated. The remaining dichloromethane was
removed under vacuum overnight. The lipid films were then hydrated with the
appropriate detergent-containing buffers, sonicated, and frozen and thawed in liquid N2
until they were fully solubilized.
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2.3

Labeling of IgG and Purification

2.3.1 Solid-phase labeling of IgG
Ni-NTA magnetic agarose beads (QIAGEN; 200 µL, 5% slurry) were washed with 1 mL
of Buffer P. The IgG to be labeled (100 µg, 1.3 nmol) was bound to beads via incubation
for 30 min at room temperature with shaking. Half-scale reactions with 100 µL beads and
50 µg IgG were also performed with no additional alterations to the procedure. In all
solid-phase reactions, 0.0037% (w/v) DM was added to facilitate mixing. The beads were
spun down, and the tube was placed on a magnetic rack to ease removal of the
supernatant fraction. The antibody was activated via addition of 2 µL of 3.75 mM sulfoSMCC (Pierce; 7.5 nmol, 5.6 equiv) and shaking for 60 min at room temperature. In a
separate reaction, 3.68 µL of 0.68 mM fluorophore with primary amino group (2.5 nmol),
0.67 µL of 0.5 M sodium borate (pH 8.2), 1.32 µL of 1 M NaF, and 0.67 µL of 7.58 mM
SPDP (Pierce; 5.0 nmol, 2 equiv) were mixed for 60 min at room temperature with
shaking. The fluorophore-SPDP reaction was stopped by addition of 0.67 µL of 7.58 mM
Tris. SPDP was reduced via addition of 0.67 µL of 8.27 mM TCEP and mixing for 15
min. The activated fluorophore was added to activated IgG and mixed overnight at 4°C.
The conjugation reaction was stopped with 1 µL of 80 mM N-acetylcysteine. The beads
were washed twice with 1 mL of Buffer P. IgG was eluted with two 50 µL volumes of
Buffer E2 for 30 min each.
The solid-phase reactions were successfully carried out with 1) the following antibodies:
1D4 (National Cell Culture), 2D7 and 3A9 (BD Biosciences), and α-FLAG (SigmaAldrich) and 2) the following fluorophores: europium trisbipyridine diamino cryptate
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(EuK) (Cisbio), Alexa 647 cadaverine, and Alexa 488 cadaverine (Invitrogen).

2.3.2 Purification and characterization of labeled IgG
When desired, combined elutions were supplemented with 0.5 mg/mL BSA and run on a
Superdex 200 10/300 GL gel filtration column in Buffer G. In some cases, the
purification step was skipped and the antibody was instead exchanged into Buffer P on
Zeba Spin Desalting Columns (Pierce) according to the manufacturer’s protocol. UV-Vis
spectra were acquired using either the FPLC in-line detector or on a spectrophotometer in
cuvette format.
EuK conjugates were stored at 4°C with 0.01% thiomersal. Alexa dye conjugates were
stored at 4°C with 0.05% sodium azide.

2.4

Mutagenesis and Plasmid Construction

The human CCR5 gene containing the C-terminal C9 epitope TETSQVAPA was in the
pcDNA3.1(+) vector (Invitrogen). Mutations were introduced using the QuikChange
Lightning Site-Directed Mutagenesis Kit (Stratagene). Primers were designed to satisfy
the manufacturer’s guidelines.
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2.5

Culturing of HEK-293 Cells and Heterologous Expression of CCR5

HEK-293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) [4.5 g/L
glucose and 2 mM glutamine (Gibco)] supplemented with 10% fetal bovine serum (FBS)
(Atlanta Biologicals) at 37°C in a 5% CO2 atmosphere. Cells were propagated by
addition of 1 mL 0.25% Trypsin-EDTA (Gibco) per plate for 5 min, dilution in fresh
media, and replating in new dishes. HEK-293T cells were transfected with human CCR5
cDNA tagged with the C9 epitope, in pcDNA3.1(+) using Lipofectamine Plus as
previously described for earlier experiments with rhodopsin (Yan et al., 2003). Briefly,
for one 10 cm plate at roughly 80% confluency, 0.75 mL of prewarmed DMEM was
mixed with 3.5 µg of plasmid DNA. To this was added 10 µL of PLUS reagent, and the
mixture was incubated for 15 min and then transferred to a separate mixture containing
0.5 mL of DMEM and 17 µL of Lipofectamine Plus. After another 15 min incubation, the
volume was increased to 4 mL with DMEM and the mixture added to HEK-293T cells at
70-80% confluence. Four hours after transfection, an additional 4 mL of DMEM
supplemented with 20% FBS was added. Cells expressing CCR5 were harvested 48 h
after transfection in PBS buffer containing the protease inhibitors aprotinin and leupeptin.

2.6

Solubilization and Purification of CCR5

2.6.1 Detergent Solubilization of CCR5
Cell pellets from 10 cm plates were lysed in 1 mL of Buffer N (supplemented with
protease inhibitors) per 5 × 106 cells. After thorough resuspension, the solution was
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probe-tip sonicated with 6 × 1 s pulses and incubated for 2 h at 4°C. The solution was
then centrifuged at 14000 rpm (20000g) using a Type 45 TI rotor for 20 min at 4°C. The
supernatant fraction was collected and stored at -80°C until further use.

2.6.2 Immunopurification of CCR5
Solubilized lysate from 2 × 10 cm plates was thawed on ice and added to 50 µL of packed
1D4-Sepharose resin with 2 mg/mL immobilized 1D4 mAb. The lysate/resin mixture was
incubated for 16 h at 4°C. The resin was transferred to a Micro-Spin column (Pierce),
centrifuged to remove the supernatant fraction, and washed twice with Buffer N. Purified
CCR5 was eluted by incubating the resin with 2 × 50 µL of Buffer E1 for 30 min.

2.7

Quantification of CCR5 with Fluorescent Ligand Binding

Solubilized CCR5 lysate from approximately one-fifth of a 10 cm plate was incubated
with 100 nM fluorescein-labeled maraviroc analogue (FL-maraviroc; generously
provided by M. Teintze, Montana State University, Bozeman, MT) and 12.5 µL of 1D4Sepharose resin (2 mg of 1D4 mAb/mL of packed resin) for 16 h at 4°C in the presence
and absence of 1 µM unlabeled maraviroc (Toronto Research Chemicals). The beads
were washed three times with Buffer N, and samples were eluted via incubation of the
beads with 1% sodium dodecyl sulfate (SDS) for 1 h at room temperature and shaking.
Eluted samples were transferred to a black 96-well round-bottom polypropylene
microtiter plate (Nunc/Thermo Fisher Scientific). A serial dilution of FL-maraviroc in 1%
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SDS was also included for a standard curve. The plate was read on a Cytofluor II
Fluorescence Multiwell Plate Reader (Perbio Science) with an excitation wavelength of
485 nm and an emission wavelength of 530 nm. A linear fit of the standard curve was
used to calculate the concentration of FL-maraviroc bound to the CCR5 lysate. The
difference between the values with and without excess unlabeled maraviroc was used to
calculate the CCR5 concentration with a correction for nonspecific binding of FLmaraviroc.

2.8

HTRF Quantification Assays

All HTRF assays were conducted with the appropriate buffer supplemented with 50 mM
NaF and 1 mg/mL BSA.

2.8.1 HTRF Standard Experiment with α-DNP
The standard experiment used commercially available reagents: 2,4-dinitrophenol (DNP)NHS, anti-DNP-EuK, biotin-BSA (Pierce), and XL665-SA. Biotin-BSA-DNP was
prepared by reacting DNP-NHS with biotin-BSA according to the manufacturer’s
protocol. Competition with DNP-NHS, which does not bind XL665-SA, was used to
demonstrate the specificity of the observed HTRF signal. Biotin-BSA-DNP (5 nM) and
XL665-streptavidin (XL665-SA, 10 nM) in PBS pH 7.0 were combined in a 1:1 ratio
(v/v) and mixed for 15 min on ice (mixture 1). From the mixture in step 1, a 10-fold
diluted solution in the same buffer was made (mixture 2). Anti-DNP-EuK was prepared
at concentrations of 2.5 and 0.25 nM. The 2.5- and 0.25-nM anti-DNP-EuK solutions
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were mixed with a serial dilution of DNP-NHS for 15 min at a 1:1 ratio (preparing series
1 and 2, respectively). Mixture 1 was combined with series 1 (25 µL each/well) and
mixture 2 with series 2 (25 µL each/well) in a 384-well microplate. The plate was
equilibrated at 4°C for at least 1 h.

2.8.2 HTRF Quantification of CCR5
Biotinylated 1D4 mAb (prepared as described (Knepp et al., 2011)) was mixed with
XL665-SA for 15 min on ice at a final concentration of 128 nM. To this was added an
equal volume of 8 nM EuK-labeled 2D7 mAb (2D7-EuK). For each well of the
experiment, 20 µL of this mixture was added to a black bottom 384-well microplate
(Greiner). Solubilized CCR5 or CCR5 in nanoscale apolipoprotein bound bilayers
(NABBs) was added to a final volume of 40 µL. The final concentrations of labeled assay
components, except where otherwise noted, were as follows: 32 nM 1D4-biotin, 32 nM
XL665-SA, and 2 nM 2D7-EuK. In competition experiments, CCR5 was preincubated
with competitors for 30 min on ice prior to addition to fluorescently labeled components
in the 384-well plate. To obtain the maximal signal, we incubated the plate overnight at
4°C.

2.8.3 HTRF Signal Analysis
Dual-channel fluorescence was measured with excitation at 320 nm and emission
collection in ten 200 µs windows at 615 and 665 nm. An acceptable signal-to-background
ratio was achieved with 5000 flashes per well. Emission counts were summed over all
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windows except the first, and the F665/F615 ratio was used as a normalized measure of
sensitized emission. As an assay-to-assay control, signal enhancement ΔF was calculated:

& F665, sample F665,negative
ΔF = $
−
$F
F615,negative
615
,
sample
%

Eq. 1

# F665,negative
!÷
! F
615, negative
"

where the negative control values are obtained from the mixed labeled components in the
absence of receptor.

2.9

Thermal Stability Measurements

2.9.1 Experimental Procedure
Detergent-solubilized CCR5 or CCR5 NABBs were diluted to a concentration within the
dynamic range of the HTRF assay, and 11 µL aliquots were added to PCR tubes. For
experiments testing the stabilizing effects of the small molecule antagonists maraviroc,
AD101, CMPD 167, vicriviroc, and TAK-779, the receptor was preincubated with 8 µM
ligand for 1 h on ice before the next step. The CCR5-containing tubes were transferred to
a Multigene Gradient Thermal Cycler (Labnet International, Inc.). The thermal cycler
was set up to apply a gradient of temperatures across a row of the heating block for 30
min except where indicated, followed by cooling to 4°C. Each sample was diluted by a
factor of 2 in the appropriate buffer, and 20 µL of the heat-treated material was added to
each well of a 384-well microplate containing 20 µL of the fluorescently labeled HTRF
components.
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2.9.2 Modeling Thermal Denaturation of CCR5
Denaturation of unliganded CCR5 in detergent solution and NABBs was modeled as a
simple first order process.
Eq. 2

[unliganded, folded] !k!
→[unfolded]

The HTRF signal ΔF is the sum of contributions from folded and unfolded receptor with
appropriate scaling factors.
Eq. 3

ΔF = α 1 [unliganded , folded ] + α 2 [unfolded ]

Because denatured receptor does not bind 2D7-EuK, α2 was set to zero. The signal is
then:
Eq. 4

ΔF = α1e− kt , with

Eq. 5

k = Ae− Ea / RT .

The curve was fit with parameters α1, A, and Ea; TM was defined as the temperature at
which one-half of the receptor is unfolded. The time of incubation is designated as t.
The temperature of incubation, T, was specified in Kelvin.

Melting of CCR5-ligand complexes was modeled similarly, but as a two-step sequence
with a first order reaction describing the irreversible conversion of the “loose” and “tight”
binding states, and a second irreversible denaturation step from the tight state. This
model assumes that no unliganded receptor exists in the system, which is likely to be true
because of the high affinity of the antagonists tested.
k1
k2
[liganded , tight , folded ] !!→
[unfolded ]
Eq. 6 [liganded , loose, folded ] !!→

The HTRF signal in this system is the sum of contributions from these three species.
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Eq. 7

ΔF = α 1 [liganded , loose, folded ] + α 2 [liganded , tight , folded ] + α 3 [unfolded ]

Again, the scaling factor for unfolded receptor, α3, was set to zero, making the total
signal:
Eq. 7

& k
#
ΔF = α 1e − k1t + α 2 $ 1 e − k1t − e − k 2t ! , with
% k 2 − k1
"

Eq. 8

k1 = A1e− Ea ,1 / RT and

Eq. 9

k2 = A2 e− Ea ,2 / RT .

(

)

The curve was fit in Origin with parameters, α1, A1, Ea,1, α2, A2, and Ea,2; TM was defined
as the temperature at which one-half of the receptor is unfolded. It is important to note
that these models assume that the conversion from the loosely to the tightly bound state
and the denaturation are irreversible processes. Moreover, we restrict our interpretation
of the model to a single derived parameter, the apparent melting temperature TM.

2.10

Immunoblot Analysis

Samples were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) (NuPage Novex 4-12% Bis-Tris Gel) and transferred onto Immobilon, a
polyvinylidene difluoride (PVDF) membrane (Millipore), according to the
manufacturer’s protocol. Membranes were probed with primary antibodies followed by a
horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody (Amersham
Biosciences GE; 1:10000). Primary antibodies used were 1D4 (National Cell Culture
Center, 1:5000) and α-His6 (Sigma, 1:5000). Signals were visualized by enhanced
chemiluminescence treatment (Amersham Biosciences GE) and exposed to HyBlot CL
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autoradiography film (Denville Scientific, Inc.).

2.11

Cell Surface Enzyme-Linked Immunosorbent (ELISA) Assay

One day post-transfection, cells were harvested from 10 cm plates in DMEM with 10%
FBS and transferred to a 96-well flat, clear bottom plate pre-coated with poly-D-lysine
(100 µL; 60000 cells/well). 48 h post-transfection, cells were washed once with DPBS
containing Ca2+ and Mg2+. Primary antibody 2D7 was diluted (1:200) in Buffer EL and
added for 1.5 h with the plate on ice. The wells were then washed twice with Buffer EL.
Cells were fixed with cold 100% MeOH for 5 min on ice, washed twice with DPBS, then
once with Buffer EL. Secondary antibody α-mouse-HRP diluted (1:2500) in Buffer EL
was added for 1 h at room temperature. The wells were washed with Buffer EL three
more times before revealing. The revealing solution was prepared by diluting H2O2 and
Amplex Red (Molecular Probes) in DPBS to final concentrations of 2 mM and 100 µM,
respectively. Each well of cells was incubated with 50 µL solution for 15 min at room
temperature. The plate was read on a Cytofluor II Fluorescence Multiwell Plate Reader
(Perbio Science) with an excitation wavelength of 530 nm and an emission wavelength of
590 nm.
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2.12

High-throughput Calcium Flux Assay

2.12.1 Transfection of HEK-293T Cells in a 384-Well Format
HEK-293T cells were transfected in a 384-well flat, clear bottom plate pre-coated with
poly-D-lysine according to the following procedure. CCR5 (10 ng/well) and Gqi5 (20
ng/well) plasmid DNA were diluted in DMEM (5 µL/well). Lipofectamine 2000 (0.075
µL/well) was diluted in DMEM (5 µL/well) and incubated for 5 min. The Lipofectamine
2000 solution was added to each DNA mixture at a 1:1 volume ratio for 20 min. Cells
were harvested in DMEM and diluted to 800,000 cells/mL. The transfection mixture (10
µL/well) and cell suspensions (10 µL/well) were added to the plate, centrifuged for 5 min
at 800 rpm, and incubated for 48 h prior to the assay.

2.12.2 Calcium Flux Assay Measurements
Calcium 4 dye (Molecular Devices) was prepared at working concentration in Buffer CF
according to manufacturer’s protocol, and 20 µL was added to each well of the assay
plate. The plate was centrifuged for 5 min at 800 rpm and incubated for 1 h at 37°C and
5% CO2. The chemokine ligand, RANTES, was diluted in Buffer CF to three times the
desired final concentration. Both the assay plate and ligand plate were transferred to a
FlexStation II instrument pre-equilibrated at 37°C. Ligand injections were performed
automatically by the instrument, and the change in fluorescence was monitored as a
function of time. The percent increase of peak fluorescence after ligand addition
compared to baseline was calculated for each time trace.
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2.13

[125I]-RANTES Binding to Whole Cells

HEK-293T cells expressing CCR5 were harvested 48 h post-transfection in DPBS. Cells
were added to a 96-well V-bottom tissue culture plate (600,000 cells/well for low volume
assays; 800,000 cells/well otherwise) depending on the concentration of RANTES to be
used. At higher ligand concentrations, a lower assay volume was desirable to minimize
reagent usage. The plate was centrifuged at 2000 rpm for 5 min and cells were
resuspended in either 20 µL (low volume assays) or 50 µL Buffer RB. In control
experiments, cells were preincubated with 10 µM maraviroc for 1 h at room temperature
prior to chemokine addition. [125I]-RANTES was added to the cell suspensions at the
desired final concentration and incubated for 1 h at room temperature. Wells were
washed at least four times with 200 µL 1x DPBS. After the last wash, cells were
resuspended in 1x DPBS and transferred to scintillation vials. The vials were counted on
a Packard Gamma Counter Model 5530.

2.14

Expression and Purification of Zap1

This procedure has been described in detail previously (Banerjee et al., 2008). The Danio
rerio apolipoprotein A-I gene (zap1) in pET28a(+) vector (Stratagene) was transformed
into BL21 (DE3) Rosetta 2 E. coli cells (Novagen). Colonies were streak purified on LBagar plates containing kanamycin and chloramphenicol. A single colony was grown in
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250 mL LB media containing 50 µg/mL kanamycin and chloramphenicol at 37°C
overnight with shaking. The starter culture was diluted 1:100 in 1.6 L of sterilized
Terrific Broth media at 37°C with shaking at 180 rpm. Cells were induced with 1 mM
IPTG when the OD600 reached 0.6 and harvested at an OD600 of 1.2. The cell pellet from
one flask was resuspended in 150 mL Buffer HZ. At this step, pellets can be stored at 80°C until further use. Cells were disrupted with a French press and lysed with 1% Triton
X-100, DNAase I, and 5 mM MgSO4 for 30 min on ice. Cell extracts were then spun at
16,500 rpm for 45 min at 4°C and the supernatant was filtered with a 0.45 µm syringe
filter. Zap1 was initially purified on a Ni-Sepharose 6 FF column (GE) connected to the
Äkta Explorer FPLC system. The column was equilibrated with Buffer TZ before loading
the supernatant. The Ni column was washed with 10 column volumes (CV) of Buffer CZ
and 10 CV of Buffer AZ, then zap1 was eluted with a 0-100% gradient of Buffer BZ in
Buffer AZ. Protein-containing fractions from the elution gradient were pooled,
concentrated using an Amicon Ultra Centrifugal Filter unit with 10 kDa MW cutoff
(Millipore), and further purified on a Superdex 200 26/60 column in Buffer GZ. Fractions
were collected and assayed for purity on an SDS-PAGE gel.

2.15

Incorporation of CCR5 into NABBs and Purification

Purified CCR5 in detergent solution (prepared as described in Chapter 2.6) was
incorporated into nanoscale apolipoprotein bound bilayers (NABBs) by the following
procedure. A number of NABBs mixtures were tested. The recipe below yielded
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homogeneous preparations. This mixture is scalable provided the final concentration of
zap1 is ≥0.5 mg/mL. The molar ratio of zap1:lipids must be held to 1:75.

2.15.1 Preparing CCR5 NABBs
Purified CCR5 was added to 3.75 nmol of zap1, 280 nmol of 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC), and 22.7 nmol of cholesterol in a total volume of 200
µL containing 1.5% sodium cholate, 0.33% DM, 15 mM Tris-HCl (pH 7.0), 75 mM
(NH4)2SO4, and 7.5% glycerol. When desired, a POPC solution containing 0.5%
Lissamine Rhodamine B-labeled 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (LRBDOPE) was used to allow visualization of NABB elution. After being vortexed and
incubated on ice for 30 min, the mixture was added to 1 mL of Pierce Detergent Removal
Resin pre-equilibrated with at least 1 column volume of Buffer S. Elution was conducted
at 4°C under gravity flow by addition of Buffer S to the column and collection of 200 µL
fractions. Fractions were analyzed for protein content by monitoring the absorbance at
280 nm.

2.15.2 Purification of CCR5 NABBs
Protein-containing fractions were pooled and applied to a Superose 6 10/300 gel filtration
column. Absorbance at 280 nm (protein) and, when applicable, 570 nm Lissamine
Rhodamine B (LRB-DOPE) was monitored with an in-line detector in the FPLC
instrument (Akta Explorer, GE). Fractions of the peak corresponding to NABBs were
combined and, if necessary, concentrated using an Amicon Ultra 30 kDa cutoff
centrifugal filter device (Millipore).
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2.15.3 Immunoprecipitation of CCR5 NABBs with a Conformationally Sensitive
Antibody
CCR5 NABBs were mixed with Dynabeads Protein G (Invitrogen) with or without 2D7
mAb (BD Biosciences) according to the manufacturer’s protocol. After overnight
incubation at 4°C, the supernatant fractions were subjected to 1D4 immunoblot analysis
as described in Chapter 2.10.

2.16

Flourescence Correlation Spectroscopy (FCS)

2.16.1 FCS Sample Preparation and Measurements
FCS samples were loaded into an Ibidi µ-Dish pre-blocked with 5 mg/mL BSA. For lowvolume (<10 µL) samples, a 4 well silicone micro-insert was used and 1 mL of water was
added outside the insert to prevent sample evaporation. FCS experiments were performed
on a Zeiss LSM 780 inverted confocal microscope using a C-Apochromat 40x / NA 1.2
water objective. ZEN software controlled the system and was used for data analysis. The
objective was focused 200 µm into the sample using reflected laser light. Laser lines,
dichroics, emission filters, and fluorescence collection windows were selected based on
the fluorophores under study. The 488 nm (Alexa 488), 561 nm (Lissamine Rhodamine
B), and 633 nm (Alexa 647) lines were used in the experiments presented. The GaAsP
detector was used for emission wavelengths <600 nm, and the PMT detector for
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wavelengths >600 nm. The confocal pinhole was set to 1.0 airy unit and automatically
aligned by scanning for the highest count rate of each laser line. FCS data were typically
acquired for either 10 or 30 × 10 s windows.

2.16.2 Synthesis of Oligonucleotide FCS standards
FCS control samples were custom synthesized by Fisher Operon. The sequences chosen
were:
Forward: GCCGTCTCTGACTGCTGATGACTACTATCGTATAGTGCGG
Reverse complement:
CCGCACTATACGATAGTAGTCATCAGCAGTCAGAGACGGC
Two versions of the forward sequence were generated. The first carried Alexa 488 at the
5’ end and biotin at the 3’ end. The second carried biotin at the 5’ end. Two versions of
the reverse complement sequence were also prepared. One was labeled with Alexa 647 at
the 5’ end and the other with biotin at the 5’ end.

2.16.3 Modeling FCS Data
The theory underlying FCS is quite complex and has been described well elsewhere,
especially in Lakowicz’s Principles of Fluorescence Spectroscopy (Lakowicz, 2006).
What follows is a brief summary of the comparatively simple models used to fit the FCS
data presented.

The autocorrelation function G(τ) of fluorescence intensity time traces I(τ) is defined as:
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Eq. 9

𝐺 𝜏 =

! ! !(!!!)
!(!) !

where the brackets indicate a time average. Substituting 𝐼 𝑡 = 𝐼 + 𝛿𝐼(𝑡), G(τ) can be
rewritten as:
Eq. 10

𝐺 𝜏 =1+

! ! !(!!!)
! !

A satisfactory analytical expression for the data in this work includes contributions from
triplet blinking, GT(τ), and translational diffusion, GD(τ):
Eq. 11

𝐺 𝜏 =1+

!
!

𝐺! 𝜏 𝐺! (𝜏)

with 𝑁 the average number of particles in the focal volume. The factor γ was set to
0.35, typical for one-photon FCS.
The expression for GT(τ) is:
Eq. 12

𝐺! τ = 1 +

!! !

!!

!!

!!!!

  

with Tt the fraction of molecules in the triplet state and τt the triplet state relaxation time.
For a single species freely diffusing in three dimensions, GD(τ) is written as:
Eq. 13

𝐺! 𝜏 = 1 +

!

!!

1+

!!

!

!

!!

!

!! !

where τD is the diffusional correlation time and S is the structural parameter defined as
the ratio of the axial focal radius wz to the lateral focal radius wr:
Eq. 14

𝑆=

𝑤!

𝑤! .

The expression is more complicated for two diffusing species:
Eq. 15

𝐺! 𝜏 =

!! !!! !! ! !!! !!! !! !
!! !! !!! !! !

where Di(τ) and Bi are the diffusion expression and brightness of each species,
respectively.
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Before fitting the data, the individual time traces were examined to confirm stationarity;
that is, the intensity does not deviate abnormally from the mean, nor drift to higher or
lower levels over the course of the measurement. Typically, fits began at τ = 1.6 or 3.0 µs
to avoid detector noise effects.

In most fits the structural parameter S was fixed based on calculations from standard
experiments. The effective focal volume V is simply:
𝑉=

Eq. 16

𝑚𝛾

𝑁!

where m is the slope of a plot of calculated 𝑁 vs. dye concentration and NA is
Avogadro’s number. The lateral focal radius is determined from the observed diffusional
correlation time:
Eq. 17

𝑤!" =

4𝜏! 𝐷

where D is the known diffusion coefficient.
The structural parameter S is then:
Eq. 18

2.17

𝑆=𝑉

!

𝜋 ! 𝑤!" !

Crosslinking and Proteolysis of Rod Outer Segment (ROS) Membranes

2.17.1 Biochemical Crosslinking of ROS Membranes
The following homobifunctional crosslinkers were used: BM(PEG)3 (Pierce), Bis-MALdPEG3 (Quanta Biodesign), and MTS-O4-MTS/MTS-O5-MTS (Toronto Research
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Chemicals, Inc.). Bovine ROS membranes were prepared as described (Bigay and
Chabre, 1994). The membranes were suspended at a concentration of 1.6 mg/mL in
Buffer C. The crosslinking reagents were solubilized in DMSO and added to a final
concentration of 200 µM (5-fold molar excess) in the dark. The bis-maleimide reactions
proceeded for 24 h at room temperature before quenching with 10 mM cysteine. The
MTS reactions were allowed to proceed for 5, 15, or 60 min at room temperature before
quenching with 20 mM N-ethylmaleimide. In control samples, the MTS reactions were
treated with 100 mM DTT after crosslinking to cleave the disulfide linkages.

2.17.2 Partial Proteolysis of ROS Membranes
The site of the crosslink was determined, in part, by partial proteolysis with thermolysin
in the dark. Crosslinked ROS membranes were resuspended in Buffer T. Thermolysin
was added at a rhodopsin-to-thermolysin ratio of 50:1 by mass. The digestion proceeded
for 6 h at 37°C and was stopped by adding 5 mM EDTA and placing the tubes on ice.
Prior to SDS-PAGE analysis, samples were solubilized in 1% DM.
Samples were resolved on NuPage Novex 4-12% Bis-Tris gels. Coomassie Blue and
silver staining were carried out with standard protocols.

2.18

Liquid Chromatography-Mass Spectrometry (LC-MS)

2.18.1 LC-MS Sample Preparation
Sample preparation for LC-MS was based on a previous study (Kraft et al., 2001).
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Crosslinked ROS membranes were solubilized in 1% DM and bleached. Bis-maleimide
samples and the MTS negative controls were treated with 15 mM DTT for 1 h, and all
samples were treated with iodoacetamide (100 mM) for 3 h. Rhodopsin was precipitated
with 10% TCA and spun at 14k rpm in a tabletop centrifuge for 5 min to produce a pale
yellow pellet. The pellet was washed with 95% ethanol in a bath sonicator three times to
remove TCA and lipids. The pellet was then dissolved in 100% TFA containing 500
molar excess CNBr per rhodopsin methionine in the sample. Water was added to give a
final concentration of 80% TFA, and the digestion proceeded overnight. Samples were
dried with argon and desiccation. When ready for LC-MS analysis, the dried precipitate
was resuspended in 20 µL ddH2O.

2.18.2 LC-MS Measurements
The samples were loaded onto a C18 5 µm trap column (LC Packings) and run at 30
µL/min, then on an in-house made C18 analytical column (75 µm diameter beads) at 0.2
µL/min. Solvent A was water + 0.1% formic acid and solvent B was acetonitrile + 0.1%
formic acid, and elution proceeded from 5-40% B over 35 min. MS was performed with 5
µL injections onto a LTQ Orbitrap XL (Thermo Scientific) with ion trap. The mass range
was 400-1600 m/z.

2.18.3 LC-MS Data Analysis
LC-MS data were analyzed on Xcalibur software (Thermo). Mass spectrometry data are
recorded as mass-to-charge ratios (m/z), but charges can be assigned to sets of isotope
peaks based on the distance between them. All charges were automatically calculated by
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the software and multiplied by the m/z values to yield absolute experimental masses.
Theoretical monoisotopic masses were calculated using the online MolE Molecular Mass
Calculator. Masses were calculated for the peptide of interest and the crosslinkers with
several chemical modifications, isotopes, and protonation states. The experimental data
were screened for these possibilities. Matches were only assigned if the peaks were
within 25 ppm error of the theoretical mass and not present in negative control samples.
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Chapter Three: A High-Throughput Method to
Measure CCR5 Stability and Characterization of
Thermally Stable Mutants*

3.1

Introduction

	
  
Decoding the complex allostery and signaling behavior of GPCRs requires
advances in both structural and biophysical studies. Despite high structural homology, the
utility of models from existing GPCR structures is somewhat limited (Patny et al., 2006).
Subtle differences in the ligand-binding pocket between subtypes can have a large effect
on specificity. High-resolution structures provide insight into the uniqueness of each
receptor, perhaps enabling development of more potent and specific drugs. However,
static portraits cannot tell the full story of GPCR signaling. GPCRs are conformationally
flexible, and the stabilization of and exchange between states is key to their function.
Dynamic studies of receptor activation and coupling between the ligand binding pocket
and intracellular surface are needed to understand this finely tuned allostery.
Fluorescence techniques are ideally suited for this task.
GPCRs present significant technical challenges that impede progress in both these
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
*
Portions of this chapter have been published previously: Knepp AM, Grunbeck A,
Banerjee S, Sakmar TP and Huber T (2011) Direct Measurement of Thermal Stability of
Expressed CCR5 and Stabilization by Small Molecule Ligands. Biochemistry 50:502511. Knepp AM, Sakmar TP and Huber T (2013) Homogeneous time-resolved
fluorescence assay to probe folded G protein-coupled receptors. Methods in Enzymology
522:169-189.
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threads of research. X-ray crystallography requires milligram quantities of pure,
homogeneous sample, but with the exception of rhodopsin, GPCRs are expressed at low
levels in native tissues (Chiu et al., 2008). This makes sense from a physiological
perspective; very high expression would presumably disrupt the sensitive and
interconnected signaling pathways that GPCRs regulate. Further, GPCRs are generally
not modular structures. That is, constructs cannot be divided into fragments and
reconstituted after purification. Recombinant expression systems for full-length GPCRs
are therefore a necessity. Unfortunately, efforts to produce GPCRs in the workhorse
expression system E. Coli typically result in misfolded protein (Lundstrom et al., 2006),
perhaps because bacteria lack the proper chaperone and post-translational machinery to
generate functional receptor. Expression in insect cells has fared better – a number of
GPCRs have been successfully overexpressed and purified from Sf9 cells, including
CCR5 (Nisius et al., 2008). In theory, mammalian cells should be the ideal expression
system of choice. While these cell cultures generate samples with high levels of activity,
they are difficult to scale effectively and heterogeneity of post-translational modifications
can make crystallization exceedingly difficult. Generation of cell lines with more uniform
glycosylation profiles, as has been achieved with rhodopsin, can circumvent this problem
(Reeves et al., 2002). Still, doing so may require considerable effort.
Stabilizing GPCRs outside of their native environments poses an even greater
challenge, and one that affects both structural and biophysical work. As with any
membrane protein, detergents must be used in solubilization to disrupt the biological
membrane and to mimic the amphipathicity of the bilayer. GPCRs are fragile structures,
however, and detergents are a poor substitute for the membrane. Solubilization thus often
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results in unfolding and aggregation. Careful selection of lipid/detergent mixtures can
result in satisfactory preparations, but because successful conditions cannot be predicted
a priori, identifying them is an empirical process. Protein engineering tricks have been
employed to improve stability, including truncations or deletions of disordered regions,
insertion of domains such as T4 lysozyme, formation of a complex with an antibody Fab
fragment, ligand binding, and introduction of a combination of stabilizing mutations
(Rosenbaum et al., 2009). The success of these strategies must be experimentally
evaluated as well.
Because of the large number of potentially stabilizing conditions and the protein
expression limitations discussed above, assays to measure sample quality should be
robust, high-throughput, and require small amounts of material. Thermal stability assays
are a useful way to analyze the comparative effectiveness of conditions. Typically,
samples are heat-treated and some readout parameter is plotted as a function of
temperature. The apparent melting temperature, TM, represents a proxy for sample
stability. While unfolding of the prototypical GPCR rhodopsin can be monitored by UVVis spectroscopy – loss of binding of the chromophore 11-cis retinal results in the
disappearance of a characteristic peak – other GPCRs do not contain an intrinsic probe
for proper folding. More general techniques to measure structural changes during
denaturation include ligand binding, changes in cysteine reactivity, static light scattering,
and surface plasmon resonance, among others (Alexandrov et al., 2008; Navratilova et
al., 2005; Serrano-Vega et al., 2008; Vedadi et al., 2006). These approaches often require
micrograms per assay, quantities that can quickly become prohibitive for GPCRs.
Fluorescence resonance energy transfer (FRET) is a highly sensitive method to
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monitor protein-protein binding. Homogeneous time-resolved fluorescence between a
europium cryptate (EuK) donor and a modified allophycocyanin (XL665) acceptor bears
particular advantages. EuK has a very long fluorescence lifetime (up to 1 ms), reducing
the negative effects of autofluorescence on the signal-to-background ratio. This FRET
pair also has an unusually large Förster radius, permitting signal detection even if
relatively long distances separate the donor and acceptor. HTRF has previously been used
to monitor ligand binding to GPCRs in cell membranes, as well as in secondary
messenger assays of downstream signaling (Albizu et al., 2007; Devigny et al., 2011).
The HTRF technology was applied to develop an assay suitable for rapid and
sensitive screens of GPCR foldedness. The method was developed for the target receptor
CCR5, but with the expectation that the overall approach should be applicable to other
GPCRs and membrane proteins in general. Despite its importance in immunology and
HIV-1 viral entry, no high-resolution structure of CCR5 is available. In fact, it has proven
to be a particularly challenging receptor to study due to its instability. Like other nonrhodopsin GPCRs, CCR5 does not possess an internal reporter of functionality. In
addition, its native ligands, chemokines, are small proteins that are difficult to express
and label. Thus, rather than rely on ligand binding, we elected to use anti-receptor
monoclonal antibodies as reporters of proper folding. The 2D7 antibody was developed
as an anti-HIV entry blocker and binds a conformationally sensitive epitope on the
second extracellular loop (Khurana et al., 2005; Lee et al., 1999). The 1D4 antibody
recognizes the C-terminal nine residues of rhodopsin, an epitope that can be engineered
into other GPCRs (Molday and Mackenzie, 1983).
The quantitative assay was developed with several goals in mind. The original
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objective was functional reconstitution of CCR5 into membrane nanoparticles called
NABBs, which were developed as a platform for studying membrane proteins in a nativelike environment (Banerjee et al., 2008). Challenges during purification and subsequent
evaluation of receptor quality motivated this work. The incorporation of CCR5 into
NABBs, demonstration of receptor integrity, and applications are discussed in detail in
Chapter 4.
Two additional applications emerged once the full utility of the HTRF technique
became apparent. One was identification of mutations that thermally stabilized CCR5.
This project was undertaken in collaboration with Heptares Therapeutics with the end
goal being the first crystal structure of CCR5. Mutagenesis carries notable advantages
over other approaches to stabilize GPCRs. Unlike fusion constructs or complexes with
bulky Fab fragments, a combination of point mutations does not necessarily result in
large structural perturbations. In particular, the intracellular region involved in binding
heterotrimeric G proteins need not be significantly altered. In addition, mutations can be
identified that stabilize a single preferred receptor conformation (Robertson et al., 2011),
with ligand-binding and cell based assays used to evaluate receptor states. Thermally
stabilized mutants, called StaRs, have been identified for several GPCRs and led to
crystal structures of the β1-adrenergic receptor and adenosine A2A receptor (Dore et al.,
2011; Warne et al., 2008). Several stable CCR5 constructs were identified; data from the
functional assays I used to characterize them are presented in this chapter.
A third application involved the determination of the allosteric relationship
between anti-HIV entry antibodies and small molecule drugs. In experiments measuring
the stabilizing effect of small molecule binding, the molecules appeared to induce unique
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receptor conformations. This had been suggested in earlier studies involving native
chemokine binding (Watson et al., 2005). Better understanding of this behavior has
implications for HIV therapy with respect to both synergism of antiviral activity and
perhaps in avoiding viral resistance to a particular receptor conformation (Ji et al., 2007).

3.2

Results

3.2.1 Solid-phase labeling of IgG
We first developed a scalable procedure for labeling small amounts of IgG with
EuK. IgG molecules bind magnetic Ni-NTA beads through a conserved histidine-rich
region of the Fc stem. For the CCR5 HTRF assay, we labeled 2D7 mAb with EuK. 2D7
and EuK were activated separately before combining for the final conjugation: 2D7 with
sulfo-SMCC and EuK with SPDP. This strategy was chosen because we found that
reducing SPDP to produce the free thiol resulted in significant breaking of IgG disulfide
linkages. When EuK is activated with SPDP, TCEP treatment is carried out in the
absence of IgG and antibody integrity is preserved. The overall reaction scheme is shown
in Figure 3-1A.
The labeled IgG was first analyzed by nonreducing SDS-PAGE (Figure 3-1B).
The gel shows that the chosen labeling strategy results in minimal fragmentation. In fact,
the labeled product appears not to contain some lower molecular weight species that were
present in the original sample. The product was supplemented with 0.5 mg/mL BSA and
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Figure 3-1. (A) Scheme depicting strategy to synthesize EuK-labeled 2D7 mAb (9).
EuK (1) is activated by addition of a sulfhydryl by reaction with SPDP (2) and reduction
by TCEP (top). Separately, 2D7 mAb (6) is immobilized on Ni-NTA resin and reacted
with sulfo-SMCC (7) to generate a maleimide derivative (8). A crystal structure of IgG
(PDB ID: 1IGY) is shown as a model. The two activated reagents are combined and
labeled 2D7 is eluted from the resin with imidazole. (B) Left: Size-exclusion
chromatography with monitoring of absorbance at 280 nm (solid; protein) and 305 nm
(dashed; EuK) to determine yield and labeling ratio. Right: Coomassie blue-stained nonreducing SDS polyacrylamide gel electrophoresis showing a single band of the intact
2D7-EuK after labeling. Note the impurities of the initial 2D7 sample have been largely
removed by the procedure. (C) Fluorescence of purified, EuK-labeled antibodies. SEC
fractions (400 µL) were collected from 8-19 mL elution and EuK emission was measured
at 615 nm. They also revealed some sample heterogeneity. The main peak is monomeric
2D7-EuK, and the earlier and later peaks are presumed to be dimeric and fragmented
IgG, respectively.
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loaded onto a Superdex 200 10/300 GL gel filtration column equilibrated with Buffer G.
We found that using BSA as a carrier protein significantly improved recovery of the
microgram sample quantities. This column resolves samples in this molecular weight
range well. Absorbance was monitored at 280 and 305 nm for protein and EuK (Figure 31B). Using known molar extinction coefficients, an approximate labeling ratio of 1.3
EuK/IgG was calculated (Lopez-Crapez et al., 2008).
To further confirm the presence of EuK, size exclusion chromatography (SEC)
fractions were collected and loaded into a microplate, and fluorescence was measured.
The peak profile corresponds very well to UV absorbance off of the column (Figure 31C). The fluorescence points were fit to three Gaussian peaks to determine the fractions
most likely to contain monomer. We estimated that 30 µg of labeled 2D7 monomer
(~90% of the total protein content) were ultimately pooled.
Having successfully established the solid-phase labeling strategy for this
particular antibody and probe, we sought to generate other useful reagents by the same
method. The 1D4 and α-FLAG antibodies, as well as a second α-CCR5 mAb, 3A9, were
conjugated to EuK with similar results. In addition, 1D4 and 2D7 were labeled with
Alexa Fluor 488 and 647 dyes carrying a reactive cadaverine moiety. Comparable yields
and labeling ratios were achieved for these conjugations. UV-Vis spectra of eluted
products are shown in Figure 3-2. These reagents could be useful in a wide range of
assays, including fluorescence-activated cell sorting (FACS), immunofluorescence, FCS,
and TIRF imaging.
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Figure 3-2. UV-Vis spectra of purified antibodies labeled with Alexa Fluor dyes using
the solid-phase method. 1D4-Alexa 488 (blue), 1D4-Alexa 647 (red), and 2D7-Alexa 647
(green) are shown. Using the peak absorbances and known molar extinction coefficients,
the labeling ratios were determined to be 1.3, 2.1, and 1.8 fluorophores/antibody for 1D4488, 1D4-647, and 2D7-647, respectively. These values are in line with results obtained
with europium cryptate labeling, indicating the generality of the procedure.
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3.2.2 HTRF Assay to Quantify Properly Folded GPCRs
Signal detection was first optimized in a system similar to the immunosandwich
in Figure 3-3. The standard experiment used anti-DNP-EuK, DNP-NHS, biotin-BSA, and
XL665-SA. Biotin-BSA-DNP was prepared by reacting DNP-NHS with biotin-BSA.
This reagent binds the EuK-labeled antibody and links to XL665 through a biotinstreptavidin interaction, bringing the donor and acceptor into proximity. We reasoned that
initial signal detection would be easier in this scheme because biotin-BSA-DNP is
smaller than the analogous CCR5-1D4 complex shown in Figure 3-3. Competition with
DNP-NHS, which does not bind XL665-SA, was used to demonstrate the specificity of
the observed HTRF signal. The signal enhancement ΔF was calculated using the wells
with a saturating concentration of DNP-NHS as a negative control. Figure 3-4 shows the
results of the standard experiment. A maximum ΔF of approximately 5 is observed in the
experiment with higher concentrations of EuK and XL665. The competition curves
demonstrate the specificity of the HTRF signal, and its robustness suggests that the
fluorescence acquisition parameters are suitable. After establishing these conditions, the
more complex immunosandwich with expressed CCR5 was characterized.
The donor/acceptor fluorescence, time-dependence, dynamic range, and
specificity of the CCR5 assay were all measured using the acquisition settings outlined in
Chapter 2.8.3. These quality control checks were necessary to ensure that the
fluorescence signal accurately reflects the quantity of folded target receptor. As controls,
the fluorescence at 615 and 665 nm was measured in the presence and absence of 1D4biotin, XL665-SA, 2D7-EuK, and CCR5 (Figure 3-5A). The bars show that 1D4-biotin
and XL665-SA in the absence of the EuK donor results in minimal counts at 615 nm and
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2D7 mAb

EuK

CCR5

XL665
1D4
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Biot

SA

Figure 3-3. HTRF sandwich immunoassay schematic. A hypothetical model of CCR5
based on the crystal structure of rhodopsin (PDB ID: 1U19) is shown. 2D7-EuK
recognizes a conformation-sensitive split epitope on the extracellular side of CCR5.
Biotinylated 1D4 (1D4-biot) binds an engineered nine-residue C-terminal epitope and is
linked to streptavidin-conjugated XL665. FRET is observed between EuK and XL665
when 2D7 binds properly folded CCR5. The Förster radius for this donor-acceptor pair is
approximately 95 Å.
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Figure 3-4. HTRF standard experiment with donor anti-DNP-EuK and acceptor XL665SA. The fluorophores are brought in proximity by biotin-BSA-DNP. Two different
concentrations of donor and acceptor were used: 0.625 nM anti-DNP-EuK/2.5 nM
XL665-SA/1.25 nM biotin-BSA-DNP (triangles) and 0.0625 nM anti-DNP-EuK/0.25 nM
XL665-SA/0.125 nM biotin-BSA-DNP (squares). The curves depict the competition of
biotin-BSA-DNP with DNP-NHS, which does not link to XL665-SA.
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Figure 3-5. (A) Assay controls with fluorescence counts at 615 nm (black) and 665 nm
(gray) after excitation at 320 nm. CCR5-specific signal is seen as a signal increase at 665
nm and decrease at 615 nm. (B) Time course of HTRF signal with detergent-solubilized
CCR5. After loading samples into a 384-well microplate, fluorescence was measured at
the indicated time points. The plate was stored at 4°C between readings. (C) A serial
dilution of CCR5 shows the dynamic range of the assay. The signal saturates at ~200%
enhancement over background. ΔF is defined as:

& F665, sample F665,negative
ΔF = $
−
$F
F615,negative
615
,
sample
%

# F665,negative
!÷
! F
615, negative
"

(D-F) Competition experiments with the 1D5 nonapeptide (D), 1D4 mAb (E), and 2D7
mAb (F) demonstrate signal specificity.
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some emission at 665 nm. 2D7-EuK without acceptor gives a strong signal at 615 nm and
some bleed-through at 665 nm. When these three components are combined in the
absence of CCR5, the 615 nm signal is close to that of 2D7-EuK alone, and the 665 nm is
only slightly greater than of the acceptor alone. This suggests that minimal FRET occurs
without the receptor to bring the donor and acceptor near each other. In the presence of
CCR5, sensitized emission is observed, with a decrease in 615 nm fluorescence and
increase at 665 nm. This results in an increased F665/F615 ratio. The time course of the
CCR5-dependent signal was measured (Figure 3-5B). The signal increases significantly
during the first few hours of incubation at 4°C as the system equilibrates, and is then
stable overnight. For maximum signal-to-background and assay reproducibility, plates
were incubated for 12–16 h before fluorescence measurement.
For quantification applications, the dynamic range of the signal must be
determined (Figure 3-5C). This was done by incubating labeled components with a serial
dilution of detergent-solubilized CCR5. A linear range precedes signal saturation near ΔF
=2. The signal was calibrated to an absolute concentration by incubating receptor
immobilized on 1D4-Sepharose beads with a high-affinity fluorescent antagonist FLmaraviroc. The amount of CCR5 in cell lysate was estimated to be 13.9 ± 0.2 nM by
comparing the fluorescent signal in the elution to a FL-maraviroc standard curve (Figure
3-6). This concentration represents a lower bound, though we assume that all folded
receptor can bind the high-affinity ligand. With this value, we estimated that 0.02–1.0 nM
CCR5 can be effectively quantified in the HTRF assay, which corresponds to 0.8–40
fmol in a volume of 40 µL. The assay is therefore remarkably sensitive. In subsequent
experiments, receptor concentrations near the middle of the dynamic range were used to
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Figure 3-6. FL-maraviroc standard curve used to bring the HTRF signal to an absolute
scale. A serial dilution of FL-maraviroc was used to generate the curve. CCR5 was
immobilized on 1D4 mAb-Sepharose beads and incubated with a saturating concentration
of FL-maraviroc. The concentration of CCR5 was back-calculated from the standard
curve.
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minimize measurement errors.
The specificity of the HTRF signal was determined in competition experiments
with a serial dilution of TETSQVAPA nonapeptide (“1D5”), 1D4, and 2D7 (Figure 35D-F). Signal enhancement ΔF was normalized to the end points of 0% and 100%
inhibition. The data were fit to sigmoidal curves, and the IC50 values for 1D5, 1D4, and
2D7 were 130, 2.7, and 0.79 nM, respectively. Having demonstrated the sensitivity and
specificity of the signal, we next focused on applying the technology to measure receptor
stability.

3.2.3 High-throughput Measurement of CCR5 Thermal Stability
CCR5 stability over time was first measured in buffer containing only 1% DM
and in the more complex lipid-detergent mixture Buffer N. Results are shown in Figure
3-7. Aliquots were stored at 4°C for the time indicated prior to measurement. Time points
shorter than the time necessary to equilibrate CCR5 with the labeled antibodies are not
accessible, but the longer-term trends are observable. Whereas CCR5 in DM alone
denatures over the course of several days, CCR5 in Buffer N is remarkably stable. This
shows additional buffer components may be necessary to achieve optimal GPCR
stability, motivating high-throughput screening techniques such as the one described.
Thermal stability is a crucial indicator of receptor tractability outside of its native
membrane environment. We adapted the HTRF assay to measure CCR5 thermal stability
under a variety of conditions. In short, a range of temperatures was applied to CCR5
aliquots for 30 min, and then the samples were cooled to 4°C and added to the microplate
containing the labeled 1D4 and 2D7 FRET pair. Plotting the ratio of the fluorescence
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Figure 3-7. Temporal stability of CCR5 solubilized in 1% DM (triangles) and a buffer
containing a complex mixture of lipids and detergents, as well as 10% (v/v) glycerol
(squares). Aliquots were thawed and stored at 4°C for the indicated time prior to
measurement.
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signal as a function of temperature generates thermal denaturation or melting curves
(Figure 3-8). Receptor denaturation, aggregation, and subsequent loss of 2D7-EuK
binding presumably cause this loss of signal.
The thermal stability of CCR5 was measured in the presence and absence of highaffinity small molecule receptor ligands. CCR5 solubilized in buffer N has a TM of 47.1 ±
0.6°C (Figure 3-8A, black). Preincubation of CCR5 with 8 µM maraviroc, AD101,
CMPD 167, vicriviroc, or TAK-779 before the application of heat conferred a significant
increase in thermal stability (Figure 3-8A-C). Maraviroc stabilizes CCR5 to the greatest
extent, shifting the TM to 66.0 ± 0.3°C (Figure 3-8A, red). The TM values for AD101,
CMPD 167, vicriviroc, and TAK-779 are 59.9 ± 1.0, 62.7 ± 2.3, 59.5 ± 1.4, and 64.1 ±
1.2°C, respectively (Figure 3-8B-C). Another interesting effect of these ligands is the
reduction of the level of 2D7-EuK binding. Preincubation with all ligands results in a
decrease in the magnitude of the HTRF signal, but to varying degrees. This indicates that
antagonist binding reduces the accessibility of the 2D7 epitope on the EC2 loop,
consistent with earlier work (Tsamis et al., 2003). This phenomenon is explored in further
detail in Chapter 3.2.5. In addition, each of these melting curves displays an increase in
the signal near 50°C before complete loss due to denaturation. This profile suggests that
at least two distinct binding states might be involved in the antagonist-CCR5 interaction,
with the “slower” being more amenable to 2D7 binding. These ligand-CCR5 denaturation
curves were modeled as a sequence of two irreversible first-order processes. It is
interesting that the conversion of the two inhibitor-bound conformations occurs around
the temperature at which the empty receptor is denatured. The molecular structures of the
antagonists tested are shown in (Figure 3-8D).
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Figure 3-8. The HTRF assay was applied to make high-throughput thermal stability
measurements with femtomole quantities of CCR5. A range of temperatures was applied
to detergent-solubilized CCR5 or CCR5 NABBs before adding to labeled HTRF
components in a 384-well plate. (A) Melting curves of unliganded CCR5 (black) and
CCR5 preincubated with the small molecule antagonist maraviroc (red). Maraviroc shifts
the TM of detergent-solubilized CCR5 from 47.1°C to 66.0°C (rightward-pointing arrow)
and appears to display a two-step binding profile. The first ligand-receptor state reduces
the accessibility of the 2D7 epitope on the EC2 loop compared with unliganded receptor
(downward-pointing arrow). The second ligand-receptor state results in a higher HTRF
signal (upward-pointing arrow). (B) Thermal denaturation of CCR5-ligand complexes.
CCR5 was preincubated with maraviroc (red), AD101 (green), vicriviroc (blue), and
CMPD 167 (cyan). All of these antagonists appear to promote two distinct FRET levels
in this immunoassay. The calculated TM for maraviroc, AD101, vicriviroc, and CMPD
167 is 66.0°C, 59.9°C, 59.5°C, and 62.7°C, respectively. The unliganded receptor, which
melts at a lower temperature, is shown as a black dashed line for reference. (C) Thermal
denaturation of CCR5 preincubated with TAK-779. The calculated TM is 64.1°C. Note
that this curve is only presented separately because a preparation of solubilized CCR5 at a
different concentration was used. (D) Molecular structures of the CCR5 antagonists
tested.
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It is important to note that these experiments probe the kinetics of receptor
denaturation rather than the equilibrium distribution. The denaturation was modeled as an
irreversible first-order process, and the data were fit using nonlinear regression analysis.
The melting temperature (TM) is defined as the point at which 50% (calculated) of the
receptor is unfolded (see Materials and Methods for a description of models and curve
fits). Error estimates for the TM values were determined by bootstrap analysis, in which
random subsets of the empirical data were fit to the model and the standard error was
calculated from the distribution of calculated melting temperatures. This yielded error
estimates of ~1-3°C.
Because the process is kinetically controlled, the apparent TM is dependent on the
time of heat treatment. The choice of a 30 min incubation time was somewhat arbitrary,
and we hypothesized that heat-treating the samples for longer would result in a shift to a
lower apparent TM. To demonstrate this effect, a set of simulated melting curves based on
the activation energy of opsin denaturation were generated (Figure 3-9A) (Hubbard,
1958). These curves show a progressive shift to lower TM values as the incubation time
increases from 2 to 128 min. These theoretical curves correspond nicely with the results
from an experiment in which the heat treatment time was increased to 120 min (Figure 39B). In fact, the actual TM extracted from this experiment was within 0.5°C of the
simulated curve based on the opsin activation energy.
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Figure 3-9. (A) Simulated melting curves of the GPCR opsin using a previously reported
value of Ea for denaturation (Hubbard, 1958). Denaturation is modeled as an irreversible,
and thus kinetically-controlled, first-order process. Each curve represents heat treatment
for a specified length of time: 2 min (red), 4 min (yellow), 8 min (green), 16 min (blue),
32 min (orange), 64 min (brown), and 128 min (cyan). The apparent TM depends on
incubation time, with longer heat treatment causing a shift to lower TM. For this reason,
it is important to interpret the TM values in this report as relative measures of receptor
stability rather than as concrete thermodynamic parameters. (B) CCR5 melting curve
with 120 min heat treatment rather than 30 min as shown in Figure 3-8. The TM shifts to
35.3°C, remarkably close to the predicted value obtained from the simulated curves. This
suggests the kinetic models used to fit the data are appropriate.
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3.2.4 Identification and Characterization of Thermally Stable CCR5 Mutants
The sensitivity and throughput of the HTRF assay lent itself to rapid screens for
mutations that stabilized CCR5 for crystallographic study. In collaboration with Heptares
Therapeutics, a variation of the HTRF formulation depicted in Figure 3-3 was developed.
The principle remained the same, but α-Myc-Terbium, 2D7-biotin, and streptavidin-d2
were used in place of 2D7-EuK, 1D4-biotin, and XL665-SA. Terbium, another long-lived
lanthanide fluorophore, and d2 are an alternative HTRF donor-acceptor FRET pair with
similar excitation and emission maxima. The d2 acceptor is only 1 kDa compared to the
105 kDa XL665, so it likely causes less steric hindrance. This assay produced nearly
identical CCR5 denaturation profiles as those presented in Chapter 3.2.3. Further,
experiments using binding of a custom radiolabeled CCR5 antagonist as a readout
yielded similar curves, except at a slightly lower TM. It could be that lower energies are
required to disrupt the ligand-binding pocket than the extracellular antibody epitope.
Analytical size-exclusion chromatography runs supported the notion that receptor melting
corresponds to a shift from largely monomeric or dimeric species to aggregates.
A number of mutations were systematically screened using a methodology that
has facilitated crystallization of both the β1-adrenergic receptor and adenosine A2A
receptor (Dore et al., 2011; Warne et al., 2008). Mutants that exhibited improved thermal
stability compared to wild type in both the HTRF and radioligand binding assays were
identified as hits, or StaRs (stabilized receptors), and subjected to further rounds of
mutagenesis. Several generations of mutants were produced each using the prior version
as a template. Data with four of these generations, termed CCR5_Nα2.1, CCR5_Nβ5.2,
CCR5_Nγ9.2, and CCR5_Nδ10.2 are presented here. The final combination of mutants,
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CCR5_Nδ10.2, increased CCR5 TM by ~20°C over wild type in 1% DM; the presence of
Ca2+ and Mg2+ cations improved stability still further. This exceptionally stable construct
could be purified even in harsher detergents such as octyl-glucoside (OG).
In parallel with crystallization efforts of our collaborators, I sought to characterize
the properties of these StaR mutants. Specifically, expression, ligand binding, ligandinduced calcium mobilization, and HIV-1 viral entry data were collected. In line with
observations from Heptares, the StaRs expressed at higher levels than wild type CCR5 in
whole cell lysates. In fact, only the mutations of CCR5_α2.1 were necessary to
significantly improve expression in lysates, as probed by western blot (Figure 3-10A). In
addition, the StaRs expressed at least as well in whole-cell ELISAs probing receptors
localized to the plasma membrane (Figure 3-10B). This shows that high expression levels
are not merely misfolded receptor.
Despite proper trafficking to the cell surface, the StaRs did not induce
intracellular calcium mobilization upon stimulation with the chemokine RANTES
(Figure 3-11A). This was true even at very high (100 nM) chemokine concentrations. The
observation that the StaRs did not mediate calcium flux led to the hypothesis that they
were locked into an inactive conformation that permits 2D7 mAb and small molecule
binding but precludes binding of the native chemokine ligand. To test this, cells
expressing wild type CCR5 and two generations of stabilized mutants were analyzed for
their ability to bind [125I]-RANTES. In experiments with a serial dilution of the
radiolabeled chemokine and in the presence and absence of the antagonist maraviroc, no
specific binding of the ligand was detected (Figure 3-11B-C). This contrasted with wild
type CCR5, which exhibited robust ligand binding even at sub-nanomolar concentrations.

66

A.#

B.#
Fluorescence*(AU)*

18000"

100
75
50
37
25
20

16000"
14000"
12000"
10000"

62D7"

8000"
6000"

+2D7"

4000"
2000"
0"

mock" wt" CCR5" CCR5" CCR5"
CCR5" β5.2" γ9.2" δ10.2"

IB: 1D4

Figure 3-10. Expression data for thermally stabilized CCR5 mutants. (A) Western blots
of whole cell lysates with 1D4 primary antibody show that constructs containing the
CCR5 α2.1 mutations are sufficient for expression at higher levels than wild type
receptor (including CCR5 D-E). Single point mutants at sites that were included in the
CCR5 β5.2 construct did not express as well (CCR5 A-C). (B) Whole-cell ELISA of
HEK-293T cells with 2D7 primary antibody and α-mouse secondary antibody. The
thermally stabilized mutants show plasma membrane expression comparable to wild type
CCR5.
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Figure 3-11. (A) Dose-response curve of RANTES-induced intracellular calcium flux.
Cells were transfected with the chimeric G protein subunit Gqi5 and wild type CCR5
(red), CCR5 β5.2 (green), or a mock transfection (blue). Cells expressing wild type
CCR5 exhibit calcium mobilization as measured by changes in Calcium 4 dye
fluorescence. The CCR5 β5.2 mutant, despite strong cell surface expression, cannot
mediate signaling through this pathway. (B) Cells expressing wild type CCR5 (blue),
CCR5 β5.2 (red), or CCR5 δ10.2 (green) were incubated with a dilution series of [125I]RANTES. The wild type CCR5 cells showed much higher radioactive counts than the
thermally stabilized CCR5 cells. (C) Preincubation of cells with a saturating
concentration of maraviroc prior to addition of 4 nM RANTES show that the thermally
stabilized mutants do not specifically bind the chemokine ligand. This suggests that the
counts for these mutants observed at higher concentrations in (B) are due to nonspecific
sticking to cells.
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6"

Finally, the StaRs were tested for their capacity to be used by HIV-1 for entry into
mammalian cells. These assays were conducted by collaborators in John Moore’s Lab.
An HIV-1 pseudovirus-luciferase reporter construct was expressed in HEK-293T cells.
U87 cells expressing CD4 and the CCR5 mutants were infected with the pseudovirus and
luciferase activity was measured 72h post-infection. Two HIV strains resistant to drug
treatments were tested alongside sensitive virus (Kuhmann et al., 2004; Marozsan et al.,
2005). Remarkably, despite the mutants’ inability to bind chemokine, all of the StaRs
were used as HIV co-receptors (Figure 3-12). The luminescence signals indicating viral
entry were roughly proportionate to receptor expression levels as measured by FACS.
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Figure 3-12. HIV entry assays using HIV-1 pseudovirus-luciferase reporter constructs.
Cells expressing CD4 and each of the CCR5 mutants were infected with sensitive virus
(blue), virus resistant to AD101 (red), virus resistant to SCH-D (green), and no virus
(purple). All of the mutants tested are effectively used as co-receptors by all of the
viruses tested.
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3.2.5 Probing the Allostery between HIV Entry Inhibitor Antibodies and Small
Molecule Drugs
As shown in Chapter 3.2.3, preincubation of CCR5 with small molecule anti-HIV
entry drugs caused different FRET signals. This effect is demonstrated more clearly in
Figure 3-13. Preincubation with 10 µM of all inhibitors tested resulted in a lower signal
compared to a negative control without inhibitor. The order from highest to lowest signal
was the following: TAK-779, maraviroc, AD101, vicriviroc, and CMPD 167. The
differences in FRET signals suggest that each small molecule stabilizes a slightly
different conformation of the receptor. This result supports the idea that GPCRs are
highly sensitive allosteric machines with many energetically accessible states.
The allosteric relationship between the small molecules and 2D7 was examined in
more detail with competition experiments. First, a serial dilution of CCR5 was measured
with concentrations of 2D7-EuK below 2 nM. This showed that acceptable signal-tobackground could be achieved with lower donor fluorophore concentrations (data not
shown). CCR5 in lysate was then preincubated with a serial dilution of each small
molecule and then mixed with HTRF components. Representative results for TAK-779
are shown in Figure 3-14A. As expected, the HTRF signal increases at higher
concentrations of 2D7-EuK; high concentrations of TAK-779 result in a decrease. Similar
experiments were conducted with vicriviroc, AD101, CMPD167, and maraviroc. A plot
of the IC50 values for these competition curves against the concentration of 2D7-EuK
shows relatively little concentration dependence (Figure 3-14B).
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Figure 3-13. HTRF measurements of CCR5 in the presence and absence of small
molecule antagonists. The total amount of CCR5 in each experiment was the same, so
differences in signal indicate that the receptor probably adopts different conformations
upon binding to each.

73

A.#

B.#

0.65
0.60

-6.5

0.55

-7.0

Log(IC50)

ΔF

0.50
0.45
0.40
0.35

-7.5
-8.0
-8.5

0.30
0.25
-11

TAK-779
vicriviroc
AD101
CMPD 167
maraviroc

-6.0

-9.0

-10

-9

-8

-7

-6

-9.6

-5

-9.4

-9.2

-9.0

-8.8

-8.6

Log([2D7-EuK])

Log([TAK-779])

Figure 3-14. (A) Competition curves between TAK-779 and 2D7-EuK. CCR5 was
preincubated with the indicated concentration of TAK-779, and then the fluorescently
labeled assay components were added with 0.5 (triangles), 1.0 (circles) or 2.0 nM
(squares) 2D7-EuK. (B) Log-log plot of competition curve IC50 values against the
concentration of 2D7-EuK for each of the antagonists tested. The flatness of each curve
indicates a relationship of noncompetitive antagonism. The small molecule binds at an
allosteric site and permits binding of 2D7.
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3.3

Discussion

CCR5 is an important family A GPCR because of its role as a primary HIV-1 coreceptor (Allen et al., 2007; Lusso, 2006). Its natural ligands, including MIP-1α, MIP-1β,
and RANTES, are potent inhibitors of HIV infection, and a number of small molecule
antagonists that block HIV entry have been reported (Kuhmann and Hartley, 2008)
(Horuk, 2009). Detailed molecular studies of purified CCR5 are important for
understanding its biological function, role in HIV entry, and mode of binding to
pharmacological agents. Its high lability in solution makes it a particularly challenging
target, even by GPCR standards. Some progress has been made, as detergent conditions
that maintain proper CCR5 folding for several hours have been identified (Navratilova et
al., 2006; Navratilova et al., 2005). These reports use binding of the well-characterized
conformationally sensitive 2D7 mAb as a reporter for receptor folding and integrity
(Farzan et al., 1999; Mirzabekov et al., 1999; Wu et al., 1997).
The challenge of generating quality GPCR samples amplifies when receptors
cannot be easily expressed at high levels, as is the case with CCR5. We estimate that 1 µg
of CCR5 can be obtained from one 10 cm plate of transfected HEK-293T cells, so an
extremely sensitive quantitative assay is desirable. Ideally, this assay should also be
capable of high-throughput screening so that a large number of potentially stabilizing
conditions can be evaluated in parallel. We decided on a strategy of HTRF, with
fluorescently labeled antibodies forming an immunosandwich on distinct epitopes of
CCR5. HTRF occurs when a EuK fluorescent donor is brought into the proximity of a
modified allophycocyanin (XL665) acceptor (Bazin et al., 2001; Mathis, 1995). The dual-
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wavelength detection of donor (615 nm) and acceptor (665 nm) fluorescence after EuK
excitation at 320 nm results in a specific signal with excellent well-to-well reproducibility
and internal correction for inner filter effects. Figure 3-3 depicts the CCR5 formulation.
The key reporter is EuK-labeled 2D7 mAb, which binds to the split epitope QKEGL-TL
on the EC2 loop of the receptor (Khurana et al., 2005; Lee et al., 1999). This FRET pair
has a Förster radius of approximately 95 Å, making signal detection feasible even though
the fluorophores are probably separated by at minimum the distance between the
intracellular and extracellular faces of the receptor.
To maximize HTRF assay sensitivity, we labeled 2D7 directly rather than rely on
a secondary antibody. Typically, conjugations require fairly large amounts of antibody
and/or fluorophore (Cummings et al., 1999; Kane et al., 2000). We therefore developed a
scalable solid-phase procedure for labeling small amounts of IgG with EuK. Solid-phase
chemistry bypasses two technical drawbacks associated with labeling reactions in
solution. First, the conjugated product is easily separated from excess reagents and side
products without chromatographic or other means. This saves several additional
purification steps and likely increases yield. Immobilization of the IgG permits simple
and thorough washing steps, particularly with magnetic beads. Second, the tethering to
beads results in significant concentration of IgG compared to commercial solutions. This
reduction in reaction volume increases the efficiency of the conjugation and eliminates
the necessity of a large molar excess of the label. Both of these advantages are
particularly noteworthy when the antibodies and/or labels are expensive, which is often
the case. To demonstrate the general utility of this method, we labeled other antibodies
with amino-derivatized fluorophores. These conjugations yielded similar results.
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After optimizing HTRF signal detection in a simplified system, we applied the
assay to detect folded CCR5. We estimate that ∼1 fmol of correctly folded CCR5 in a
single 384-microtiter plate well can be detected, far greater sensitivity than alternative
techniques. The assay is more informative than immunoblots, as it reports on the quality
of the receptor as well as the quantity. Unlike surface plasmon resonance (SPR),
conditions can be screened without the need for a common binding buffer and the timeconsuming microchip regeneration step. If automated, the HTRF approach combines
high-throughput capability and sensitivity at a level exceeding even the best available
SPR equipment, which is also more expensive (Rich et al., 2009).
We were able to make high-throughput measurements of CCR5 stability with
small amounts of material. These experiments are crucial for determining conditions for
structural studies. While DM is considered an excellent detergent for GPCR
solubilization, the data in Figure 3-7 suggest that more complex detergent/lipids mixtures
are required to obtain satisfactory stability. The HTRF assay is well suited to screen the
large number of potential salts, detergents, and lipids. CCR5 retained proper folding in
the well-performing buffer, which includes cholesterol hemisuccinate (CHS), even after
being heated at >40°C for 30 min, and for up to 48 h at 4°C. CHS has previously been
shown to stabilize a number of GPCRs (Chiu et al., 2008). Preincubation with small
molecule CCR5 antagonists resulted in a marked shift of the TM to 59-66°C. These
temperatures compare favorably with GPCRs that were successfully crystallized, for
example the β1-adrenergic receptor (Serrano-Vega et al., 2008).
The thermal stability experiments performed probe the kinetics of denaturation
rather than the equilibrium distribution. The experimental results are modeled
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accordingly. We hypothesize that the receptor-ligand complex proceeds through a series
of conformational states: a “loose” antagonist-bound state, a “tight” antagonist-bound
state, and finally, a denatured state. A similar multistep process with a final irreversible
step has been previously proposed to describe rhodopsin denaturation using differential
scanning calorimetry data (Landin et al., 2001). The authors of that study concluded that
the denaturation step is rapid compared to any reversible step and thus that the process is
kinetically controlled. The fitting parameters used in this work include thermodynamic
quantities necessary to derive an appropriate rate constant for these transitions, but we
restrict our interpretation to a single value, the apparent melting temperature, TM.
Thus, there is no sharp inherent transition temperature for a kinetically-controlled process
such as GPCR melting, and the length of time the receptor is heat treated was chosen
simply so that it is experimentally relevant and informative.
Our thermal stability results were validated in the hands of our collaborators at
Heptares Therapeutics, both in a variation of the HTRF assay and in radioligand binding
experiments. Further, size-exclusion chromatography runs of heat-treated receptor
confirmed that the observed “melting” corresponds to transitions from mostly monomeric
populations to higher-order oligomers and finally, aggregates of denatured protein.
Heptares used these tools to identify combinations of mutations that resulted in
exceptionally stable CCR5 constructs. This work was motivated by the goal to solve the
crystal structure of CCR5 either in complex with the HIV envelope glycoprotein gp120
or, at least, in a conformational state relevant to infection. Point mutations perturb the
native structure less than large protein insertions, making this an attractive strategy.
The mutations that conferred improved stability were distributed throughout the
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extracellular and intracellular loops as well as the transmembrane helices. In order to
understand the effects of the mutations on receptor function, a series of expression and
pharmacological assays were conducted. Encouragingly, StaRs expressed at even higher
levels than wild type CCR5 in HEK-293T cells. The stable mutants may be more
resistant to misfolding and degradation. Despite considerable expression at the plasma
membrane, as measured by ELISA, the mutants did not induce intracellular mobilization
in response to RANTES treatment. This was the case even at very high (100 nM) ligand
concentrations. The signal-dead result could be explained several ways: inability to bind
chemokine, inability to form an active conformation, and formation of an oligomeric state
inconducive to G protein coupling among them. The ligand-binding hypothesis was
tested by incubating cells expressing the CCR5 mutants with [125I]-RANTES. These
experiments showed that none of the StaRs are able to bind chemokine with nanomolar
affinity. It is therefore likely that the mutations lock the receptor into an inverse agonistlike state. This would make sense, as it has been shown that GPCR mutants with greater
conformational flexibility – and thus reduced thermal stability – exhibit higher
constitutive signaling activity (Gether et al., 1997). Despite the StaRs’ inability to bind
chemokine, it was shown that they are effectively used as HIV co-receptors by both drugsensitive and drug-resistant viruses (Figure 3-12). This somewhat surprising result has
interesting implications. First, if any of these mutants are successfully crystallized, it
would probably be in a conformation that supports HIV infection, clearly a desirable
characteristic. The data also suggest that a signaling-competent co-receptor is not
necessary for viral entry, supporting the prevailing view (Lusso, 2006).
The antagonists maraviroc (Dorr et al., 2005), AD101 (Trkola et al., 2002),
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CMPD 167 (Veazey et al., 2003), vicriviroc (Strizki et al., 2005), and TAK-779 (Baba et
al., 1999) block interaction of CCR5 with the HIV envelope glycoprotein gp120 and
demonstrate high antiviral potency. Maraviroc is the first FDA-approved GPCR-specific
HIV entry inhibitor. Key residues in the transmembrane domains that are required for
antagonist binding have been identified, but precisely how gp120 inhibition occurs
remains unknown (Kondru et al., 2008; Seibert et al., 2006). The melting curves
generated demonstrate that ligand-receptor complexes under optimized conditions could
be sufficiently stable for high-temperature nuclear magnetic resonance (NMR) or
crystallization studies. These structures could be particularly interesting because some
HIV variants that are resistant to small molecule inhibitors have been identified
(Kuhmann et al., 2004; Marozsan et al., 2005). The denaturation profiles also shed some
light on the binding dynamics of the CCR5 antagonists, which appear to consist of two
steps. The first state, with induces a decreased HTRF signal, could be due to slightly
decreased 2D7-EuK affinity or an alteration of the antibody binding orientation that
results in a longer donor-acceptor distance. The second state, characterized by a notable
rise, seems to more closely resemble CCR5 in the absence of antagonist. A similar twostep binding profile has been proposed for β2-adrenergic receptor ligands (Deupi and
Kobilka, 2007). Interestingly, the five antagonists tested inhibit 2D7-EuK binding to
varying extents, but none completely (Figure 3-13). It is unsurprising that the antibody
and small molecule can co-bind, as the antibody binds an epitope on the EC2 loop and
the small molecules bind a more buried transmembrane region. Competition experiments
revealed a relationship of noncompetitive antagonism (Figure 3-14). Antibody and small
molecule therapeutics can thus be used synergistically, as previously suggested (Watson
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et al., 2005). Further, the varying HTRF signals suggest that the small molecules stabilize
different receptor conformations with a common inability to support HIV entry. Earlier
studies involving ligand binding to whole cells came to similar conclusions (Ji et al.,
2007). Such a situation may motivate a sequential treatment strategy to overcome viral
resistance, though cross-resistance to drugs has been demonstrated (Pugach et al., 2008).
Additionally, the conformational complexity of these GPCR-ligand complexes make
them ideal candidates for single molecule fluorescence experiments probing receptor
allostery, which will be discussed in the following chapter.

81

Chapter Four: Incorporation of CCR5 into Membrane
Nanoparticles and Single Molecule Fluorescence
Measurements*

4.1

Introduction

	
  
GPCRs, like all membrane proteins, are difficult to study outside of their native
membrane environment. A solution of membrane proteins in aqueous buffer will not stay
monomeric because of the hydrophobic effect, which drives transmembrane helices to
interact with each other. Aggregation and precipitation inevitably result. Careful
screening of solubilization conditions, using methods such as the one described in the
previous chapter, can help identify favorable combinations of lipids and detergents that
overcome protein-protein interactions. Nonetheless, the study of GPCRs in detergents has
limits even under relatively stabilizing conditions. The best performing detergents for
these samples typically have a relatively low critical micelle concentration and a large
micelle size, which can lead to aggregation phenomena that complicate interpretation of
results (Bartfai et al., 2004). Furthermore, G protein activity is sharply limited by
detergent concentration, making the study of reconstituted ligand-receptor-G protein
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Portions of this chapter have been published previously: Knepp AM, Grunbeck A,
Banerjee S, Sakmar TP and Huber T (2011) Direct Measurement of Thermal Stability of
Expressed CCR5 and Stabilization by Small Molecule Ligands. Biochemistry 50:502511. Knepp AM, Sakmar TP and Huber T (2013) Homogeneous time-resolved
fluorescence assay to probe folded G protein-coupled receptors. Methods in Enzymology
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“signalosomes” in solution impractical (Ernst et al., 2007). Clearly, an ideal platform for
functional studies of GPCRs involves purification and reconstitution into a membrane
bilayer.
Nanodisc technology has surged in popularity recently (Popot, 2010). These
membrane nanoparticles are comprised of phospholipid bilayers encapsulated by helical
amphipathic belt proteins derived from high-density lipoprotein apo A-1. The properties
of nanodiscs have been studied by techniques such as small-angle X-ray scattering,
electron microscopy (EM), atomic force microscopy and size-exclusion chromatography
(Nath et al., 2007). Nanodiscs are relatively monodisperse and generally 10-20 nm in
diameter, with the size varying depending on the belt protein employed. They bear
several advantages for GPCR functional studies. First, the lipid bilayer is highly similar
to the native environment, and the lipid composition can be varied. Second, both the
extracellular and intracellular faces of the receptor are solvent-accessible. This enables
reconstitution of multicomponent signaling complexes involving receptor interactions on
both sides of the membrane. Finally, the receptor incorporation rate can be controlled by
changing the ratio of receptors to belt proteins. In this way, one can preferentially isolate
and study monomers or dimers.
NABBs (nanoscale apolipoprotein bound bilayers) are a type of nanodisc
developed in the Sakmar Lab that utilizes zebrafish rather than human apo A-1 (Banerjee
et al., 2008). NABBs are especially stable nanodiscs due to the high lipid affinity and salt
bridging properties of zebrafish apo A-1 (zap1). The first report of GPCR NABBs
described the incorporation and characterization of rhodopsin. Rhodopsin monomers
were shown to efficiently activate G proteins in these structures; a similar result was
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obtained with β2-adrenergic receptor in nanodiscs (Whorton et al., 2007).
We sought to incorporate CCR5 into NABBs for functional studies. Because
CCR5 is generally unstable and cannot be expressed in large quantities, we desired a
modular and reproducible approach that could be conducted on a microscale. This
chapter describes a method that meets these criteria. Purified receptor is first mixed with
selected detergents and lipids. NABBs are formed upon detergent extraction. The NABBs
preparation is cleaned up by purification on a size-exclusion column and the quality of
CCR5 NABBs can be evaluated using the HTRF assay for folded receptor. In this way, a
number of conditions were tested. After a satisfactory preparation protocol was achieved,
the samples could be used in proof-of-concept experiments for single molecule platforms
under development within the lab.
Though single molecule fluorescence techniques are very difficult to master, they
also hold great promise. The number of publications employing them is increasing
rapidly (Cornish and Ha, 2007). Visualizing individual receptors at work circumvents the
problems of time and ensemble averaging, making detailed kinetic information accessible
even when reaction trajectories cannot be synchronized. These types of data are crucial
for a full understanding of receptor allostery upon binding a native ligand or drug (Huber
and Sakmar, 2011). Additionally, the precise stoichiometry of complexes can be directly
observed over time, which may resolve fundamental questions about the composition of
the signalosome during different stages of the G protein cycle (Nobles et al., 2005;
Oldham and Hamm, 2007).
In this chapter, progress toward studying CCR5 by a near single molecule
technique is described. Fluorescence correlation spectroscopy (FCS) is based on the
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measurement of fluctuations in intensity as a small number of molecules diffuse through
a tiny (<1 fL) confocal volume (Lakowicz, 2006). The autocorrelation function between
intensity at a given time t and later time t + τ reveals information about the number of
molecules in the observed volume as well as their diffusion coefficient. Larger molecules
diffuse more slowly than smaller ones, causing a shift in the correlation curve. FCS has
previously been used to evaluate preparations of membrane nanoparticles (Gao et al.,
2011; Nath et al., 2010). It has also been applied to monitor small molecule and peptide
binding to GPCRs in cells, where the differences in diffusion time between bound and
unbound fractions are very large (Briddon et al., 2004; Hegener et al., 2004; Pramanik et
al., 2001). However, because diffusion coefficients exhibit weak dependence on
molecular weight, FCS does not perform as well in purified systems, especially with
larger ligands. Fluorescence cross-correlation spectroscopy (FCCS), which relies on the
correlation between two fluorescence channels, circumvents this problem. When both the
ligand and receptor are labeled, an FCCS signal will only be observed when the probes
are codiffusing (i.e. bound). This improves resolution compared to traditional one color
FCS and expands the types of interactions that can be studied effectively.
FCS features several notable advantages and disadvantages that are
complementary to total internal reflection fluorescence (TIRF), another single molecule
technique under development in the lab. TIRF occurs when a beam of light meets an
interface between two media with different refractive indices and the angle of incidence
exceeds the critical angle. The resulting evanescent wave decays exponentially along the
z-axis, confining the focal volume to a thin slice above the cover slide. This volume is
small enough that signal-to-background ratios suitable for single molecule detection can
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be achieved. Samples under study must be tethered to the surface, as opposed to the
solution-based FCS method. Though this can be technically difficult, immobilized
molecules can be observed for very long periods of time – typically until they
photobleach. This enables study of dynamic processes, such as ligand binding and
dissociation, that may take place over minutes rather than milliseconds.
Because FCS measures samples quickly diffusing through the focal volume,
photobleaching does not present the limitation it does in TIRF. The two methods also
access different timescales: µs dynamics (faster than diffusion) for FCS, and ms to
minutes for TIRF. TIRF involves “true” single molecule detection, whereas FCS usually
measures several molecules at once. Over the course of a single FCS measurement, many
molecules pass through the focal volume, so the data set statistics are very good. Taken
together, these two methods form a powerful next-generation toolkit for the study of
purified GPCRs, signaling partners, and allosteric modulators such as small molecule
drugs. The experiments in this chapter report the development of necessary standards as
well as preliminary characterization of CCR5 NABBs.

4.2

Results

4.2.1 Incorporation of CCR5 into NABBs
The first studies demonstrating formation of NABBs reported the incorporation of
rod outer segment bovine rhodopsin (Banerjee et al., 2008). Unlike rhodopsin, CCR5
cannot be purified in large quantities from natural sources, so we employed a microscale
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Figure 4-1. Protocol for incorporation of CCR5 into NABBs. Cell pellet is solubilized in
detergent buffer and an immunoaffinity purification enriches for CCR5. Solubilized
CCR5 is mixed with zap1 belt protein, lipids, and detergent. Hydrophobic affinity
chromatography removes the detergents and NABBs are formed. CCR5 NABBs are
enriched by size-exclusion chromatography. The HTRF assay is used in conjunction
with immunoblots to determine the recovery and quality of CCR5 for optimization
purposes.
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procedure to reconstitute CCR5 in NABBs. The general procedure is outlined in Figure
4-1. CCR5 expressed in HEK-293T cells was immunopurified from solubilized lysate
using 1D4-Sepharose beads. After several washing steps, receptor was eluted by addition
of 1D5-nonapeptide. Roughly one-half of the receptor is lost in this purification step
because of incomplete elution from the beads. The NABB assembly mixture was formed
by combining purified zebrafish Apo-A1 (zap1) and lipids at a molar ratio of 1:75. This
ratio was shown to yield 10-12 nm diameter disks in the earlier rhodopsin study. Purified
CCR5 elution was added to the mixture and, after incubation on ice, applied to a
detergent-removal resin. NABBs were eluted under gravity flow by addition of detergentfree buffer, and fractions were collected. Protein-containing fractions were determined by
measurement of 280 nm absorbance and pooled. UV-Vis spectra of NABBs with and
without rhodamine-labeled DOPE doped into the lipid mixture are shown in Figure 4-2A.
As a reference, NABBs containing opsin labeled with Alexa 647 according to a
previously reported procedure are also shown (Figure 4-2B). As mentioned above, CCR5
cannot be purified in large quantities like rhodopsin, so it is difficult to obtain UV-Vis
spectra showing incorporation of labeled receptor.
Combined elutions from the detergent removal resin were run on a gel filtration
column for characterization and purification (Figure 4-3A). Co-elution of protein and
lipids was monitored by measuring absorption at 280 and 570 nm, which detected
rhodamine-labeled DOPE doped into the lipid mixture. Immunoblots showed the relative
content of CCR5 (1D4 mAb detection) and zap1 (α-His6 mAb detection) in each fraction.
The majority of the CCR5 NABBs elute at 15.6 mL in the shoulder of the first peak,
which is centered at ∼16.1 mL. The second peak, at ∼17 mL, contains mainly empty
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Figure 4-2. UV-Vis spectra of NABBs formed by detergent removal over a hydrophobic
affinity resin. (A) NABBs with and without Lissamine-Rhodamine B-labeled lipids
doped into the lipid mixture. (B) NABBs containing opsin labeled with Alexa 647 show
that the procedure results in GPCR-containing NABBs.

89

A.

B.

18.6 ml
– 280nm
– 570nm

17.0 ml

16.1 ml

- 2D7

Zap1

+ 2D7

5 mAU

– 37 kDa, 1D4

– 37 kDa, 1D4
– 30 kDa, α-His6

D.

0.6
0.5
0.4
0.3
0.2
0.1
0

0.35
0.3
0.25
ΔF

ΔF

C.

0.2
0.15
0.1
0.05

0

0.2
0.4
0.6
0.8
relative [CCR5-NABBs]

0

1

CCR5-NABBs

CCR5-NABBs + 1µM
1D4

Figure 4-3. (A) Chromatogram showing co-elution of NABBs protein (blue; 280 nm)
and fluorescent lipids (red; 570 nm). The 1D4 immunoblot below shows that CCR5
NABBs elute in the peak centered at 15.6 mL, exhibiting a larger hydrodynamic radius
than the majority of the NABBs at 16.1 and 17.0 mL. The anti-His6 blot detects Histagged zap1 belt protein. Free zap1 elutes at 18.6 mL (inset). (B) CCR5 NABBs were
incubated with Protein G beads and 2D7, and the supernatant fraction was probed with a
1D4 immunoblot. The majority of CCR5 in NABBs is immunoprecipitated by 2D7,
indicating properly folded receptor. (C) HTRF signal from a serial dilution of CCR5
NABBs, demonstrating the ability to quantify properly folded CCR5 in NABBs. (D) The
HTRF signal is efficiently competed with 1 µM 1D4, showing signal specificity.
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NABBs. In the previous study of rhodopsin NABBs reconstituted at a similar ratio, it was
also observed that the receptor-containing NABBs elute ∼0.5 mL earlier than the
majority of empty NABBs. Note that the ratio of CCR5 to NABBs is approximately
1:100. This reduces the likelihood of incorporating more than one receptor per NABB
and favors a relatively homogeneous CCR5 NABB preparation. Free zap1, which elutes
at ∼18.6 mL (Figure 4-3A, inset), likely constitutes the right peak shoulder that is rather
lipid-poor as judged by the 570 nm absorbance. The CCR5 NABBs were mixed with
Protein G beads with (left) and without (right) 2D7, and the supernatant fractions were
subjected to 1D4 immunoblot analysis (Figure 4-3B). The near-quantitative
immunoprecipitation of CCR5 NABBs with the conformationally sensitive 2D7 antibody
suggests that most of the receptor is properly folded.
The HTRF assay was used in conjunction with gel filtration chromatography and
immunoblot analysis to facilitate optimization of preparation conditions. The HTRF
assay complements immunoblots because it reports on receptor folding, not just the total
amount of receptor protein. Moreover, the HTRF assay is much more quantitative and
reproducible. 2D7-EuK and 1D4-biotin bind to CCR5 in NABBs, resulting in a dynamic
range for the HTRF assay as with the detergent-solubilized receptor (Figure 4-3C).
Competition with 1 µM 1D4 ablates the signal, demonstrating signal specificity as in
detergent solution (Figure 4-3D). Assay conditions were identical to those in detergent
experiments, except that phosphate-buffered saline (PBS) was used as the starting buffer.
Using the HTRF signal as a guide, a number of conditions were screened for
optimal formation of CCR5 NABBs containing correctly folded receptor. Variables
included changing the detergents used, the zap1:lipid ratio, the lipid composition, and the
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detergent-removal resin elution buffer. We found that several factors were particularly
important for optimal CCR5 recovery. Elution of CCR5 from 1D4-Sepharose beads in
buffer N and inclusion of 0.3% (w/v) n-dodecyl β-D-maltopyranoside (DM) in the final
NABB mixture enhanced stability. Notably, the detergent removal resin adequately
extracted DM despite its low critical micelle concentration (CMC). Additionally,
equilibrating and eluting from the detergent removal resin with buffer S, 20 mM Tris-HCl
(pH 7.0), 0.1 M (NH4)2SO4, and 10% (v/v) glycerol further increased recovery.
Comparing the HTRF signal from CCR5 NABBs to that of the solubilized CCR5 starting
material, the overall yield of correctly folded receptor in the optimized procedure was
>15%. This estimate likely represents a lower bound because the NABB might prevent
head-to-tail donor-acceptor interactions that theoretically may cause a reduction in the
donor-acceptor distance and an increase in HTRF signal intensity in detergent. Indeed, it
appears that the HTRF signal at a saturating concentration of CCR5 NABBs is weaker
than the maximal signal in detergent solution (Figure 3-5B).
Thermal stability measurements were made for CCR5 NABBs using the HTRF
assay (Figure 4-4). There are several notable features of the CCR5 NABB melting curve.
The TM was 54.5 ± 3.4°C, suggesting that incorporation into the native membrane-like
environment of NABBs improves the thermal stability of CCR5. Additionally, the
temperature range over which the magnitude of the signal decreases is significantly
broadened compared with that of solubilized CCR5, suggesting some sample
heterogeneity or a lower activation energy associated with denaturation. It is also possible
that heat treatment results in melting of the NABB before unfolding of CCR5, which
would cause the receptor to aggregate.
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Figure 4-4. Melting curve of CCR5 NABBs. The assembly denatures at 54.5°C. CCR5
NABBs melt over a much broader range than CCR5 in detergent solution, suggesting
some sample heterogeneity or a distinct denaturation pathway.
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4.2.2 Fluorescence Correlation Spectroscopy Measurements of Oligonucleotide
Standards and CCR5 NABBs
Fluorescence correlation spectroscopy (FCS) is a sensitive microscopy technique
that relies on the fluctuating intensity from small numbers of molecules diffusing through
a confocal volume. The autocorrelation function of the intensity trace reveals information
about the concentration, size, and dynamics of the diffusing species. Additionally, ligandreceptor interactions can be quantitatively measured, especially when a second color is
used and the two channels are cross-correlated. This technique is called fluorescence
cross-correlation spectroscopy (FCCS) and the same general principles apply. We sought
to characterize CCR5 NABBs using these approaches. NABBs are a particularly
advantageous platform for FCS studies because the particles are freely diffusing and
relatively small.
Prior to studies with NABBs, we developed a system of standards to calibrate the
microscope system, ensure the reproducibility of measurements, and determine ideal
fitting models. Serial dilutions of free dyes, Alexa 488 and Alexa 647, were first
measured to determine the dynamic range of the FCS system. The average number of
particles in the confocal volume is determined by the y-intercept of a fit to the
autocorrelation function (Ferrand et al., 2011). Plotting this number against the dye
concentration produces the FCS standard curves (Figure 4-5). The curves are linear,
indicating that the nanomolar concentration range is suitable. Further, the slopes can be
used to determine the effective focal volume for each laser excitation line (from Eq. 16 in
Chapter 2.16). The focal volumes at 488 nm and 633 nm were calculated to be 0.32 fL
and 0.51 fL, respectively. These sub-femtoliter volumes are within the range expected
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Figure 4-5. FCS standard curves for Alexa 488 (A) and Alexa 647 (B). The calculated
average number of particles in the focal volume is plotted against the dye concentration.
The slope of this curve was used to calculate focal volumes of 0.32 fL and 0.51 fL for the
two dyes.
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and acceptable for FCS studies. Average diffusion correlation times for Alexa 488 and
Alexa 647 were 42 µs and 63 µs in the setup. These values, along with known reference
diffusion coefficients (Kapusta, 2010; Petrasek and Schwille, 2008), can be inputted into
Eq. 17 and Eq 18 of Chapter 2.16 to calculate the lateral radius and translational
structural parameter, which is defined as the ratio of the axial radius to the lateral radius.
The lateral radius and structural parameter of Alexa 488 were 270 nm and 2.9; for Alexa
647, the figures were 290 nm and 3.8.
Because complementary oligonucleotides anneal with high efficiency, we
reasoned that they would serve as useful codiffusion probes. Oligos carrying Alexa 488
and Alexa 647 were custom synthesized (Fisher Operon) to generate standards for FCCS.
The sequences were 40 base pairs – long enough to avoid FRET – and were chosen based
on a previous study (Schwille et al., 1997). These reagents are depicted in Figure 4-6A.
The autocorrelation curves for the oligos are presented in Figure 4-6B alongside those of
the free dyes. As expected, the larger oligos diffuse through the confocal volume more
slowly, with calculated diffusion times of 380 µs (Oligo 1) and 320 µs (Oligo 3). Note
that in this plot, the correlations were normalized so that shifts in diffusion time could be
easily visualized. For FCCS measurements, the oligos were annealed with a slow cool
from 77°C to 55°C. Binding causes the Alexa 488 and Alexa 647 dyes to diffuse through
the focal volume together, which we expected to result in cross-correlation between the
488 nm and 633 nm excitation lines. In contrast, a mixture of the two free dyes should
show no cross-correlation. Indeed, this was the case. The results of the FCCS
experiments are shown in Figure 4-6C. As predicted, the annealed oligos diffuse together
with a longer diffusional correlation time, 510 µs, compared to the individual oligos.
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Figure 4-6. (A) Cartoon diagram of the oligonucleotides synthesized as FCS and FCCS
standards. Oligos 3-4 are the reverse complement sequence of oligos 1-2. The biotin
handles were included so the oligos could be captured in future total internal reflection
fluorescence experiments. (B) Correlation curves of Alexa 488 and Alexa 647 dyes
(purple, green) and oligos (red, blue). The oligos are larger species and therefore diffuse
through the focal volume more slowly, hence curves shift to the right. (C) Crosscorrelation experiments with a mixture of Alexa 488 and Alexa 647 dyes as well as
annealed oligos carrying the two labels. Significant cross-correlation between the two
channels is observed for the annealed oligos, in which the dyes co-diffuse. In contrast, the
mixed dyes do not cross-correlate.
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NABBs were first characterized by FCS with Lissamine Rhodamine B-labeled
lipids doped in, as shown in Figure 4-2A. The labeled lipids enabled tracing of the
particles through the confocal volume and evaluation of the preparation’s
monodispersity. Correlation curves of NABB-LRB samples are presented in Figure 4-7A.
Two different concentrations of the LRB lipids are shown. The higher concentration has a
lower y-intercept, as predicted by FCS theory (Chapter 2.16 Eq. 11). There was some
variability from experiment to experiment in the diffusion time of NABB samples, but
the profiles were typically best fit to two components. A faster component of ~500-700
µs likely corresponded to NABBs; a slower component of 1000-2000 µs was probably a
small number of aggregates or vesicles. The variations suggested some sample
heterogeneities, which increased over time. For example, NABBs left at 4°C for one
week after preparation showed a large number of vesicles, which were indicated by large
spikes in the intensity trace (Figure 4-7B). Traces with these abnormalities had to be
discarded because they skewed the average intensity. We found that dilution of NABBs
to 100 nM, rather than a more typical >1µM, resulted in significantly more aggregates. It
appears that dilution of the particles favors their fusion. In addition, qualitative
assessment of the traces for vesicle spikes allowed us to determine suitable storage
conditions for NABBs. NABBs supplemented with 50% glycerol and stored at -20°C
displayed few aggregates for at least a week.
Opsin labeled with Alexa 647 was incorporated into NABBs (as in Figure 4-2B)
and subjected to FCS measurements. Compared to freely diffusing dye, the curve is
significantly shifted to longer correlation times (Figure 4-7C). In addition, the NABBs
curve is more complex, reflecting the sample heterogeneity mentioned above. In some
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cases, the receptor-loaded profiles were better fit when a rotational diffusion component
was included, a feature that has been mentioned previously (Gao et al., 2011). However,
this was not always the case and, in general, the simplest possible model was used to fit
the data. To demonstrate a binding experiment, Alexa 647-labeled 2D7 mAb (prepared as
described in Chapter 3.1) was incubated with empty NABBs and CCR5 NABBs (Figure
4-7D). The expectation that binding to CCR5 would cause a shift in the diffusion time
was borne out. While the change is fairly small, as predicted, future experiments with
both a labeled receptor and labeled antibody or ligand should show significant signal
above a negative control in FCCS measurements. In addition, they should enable
measurement of binding constants because both free and bound ligand can be quantified.
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Figure 4-7. FCS experiments with NABBs. (A) Correlation curves of NABBs carrying
30 nM (red) and 5 nM (green) LRB-labeled lipids. The difference in y-intercept reflects
the difference in lipid concentration. (B) Example of a spike in intensity due to diffusion
of an aggregate through the focal volume. Traces with features like this were not included
in the data fits. (C) Alexa 647 dye (blue) and Alexa 647-labeled opsin in NABBs. The
NABBs are best fit to a two-component translational diffusion model. (D) Alexa 647 dye
(blue) and Alexa 647 labeled 2D7 incubated with empty NABBs (purple) and CCR5
NABBs (cyan). The shift in diffusion time indicates that the antibody binds the receptor
in NABBs.
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4.3

Discussion

	
  
We report a rapid, microscale procedure to incorporate purified CCR5 into
membrane nanoparticles called NABBs. NABBs possess a lipid bilayer defined by the
experimental conditions, which can be optimized using the HTRF immunosandwich
assay described in Chapter 3. The best procedure results in a >15% overall yield of CCR5
with the majority of the receptor able to bind 2D7. Furthermore, incorporation of CCR5
into NABBs confers improved thermal stability compared to detergent solution, and
effect that was also observed with rhodopsin in NABBs. (Banerjee et al., 2008). The
native-like lipid bilayer of NABBs could be a particularly attractive platform for studies
of receptor activation because GPCR aggregation phenomena endemic to detergents are
of less concern (Jastrzebska et al., 2004). In addition, because the expression,
purification, and NABB formation steps can be scaled, adequate quantities of CCR5
NABBs for structural and biochemical studies should be attainable, especially using
inducible suspension-adapted stable cell lines or Sf9 insect cells.
FCS is a versatile technique for obtaining dynamic information from systems in
solution, such as NABBs. Though the theory of FCS was largely worked out in the 1970s
(Magde et al., 1972), the technical difficulties associated with the method rendered it
largely inaccessible to non-specialists until more recently. FCS has been applied to the
study of GPCRs, primarily to study the diffusion of receptors in membranes or in screens
to identify ligand-receptor interactions (Briddon and Hill, 2007). We first developed a set
of standards for our microscope system that included free Alexa Fluor dyes as well as
labeled oligonucleotides. These simple samples enabled calibration of the system,
measurement of the dynamic range and focal volume, and identification of fluorophores
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suitable for these techniques. Alexa 488 performed particularly well, displaying high
photon counts rates at nanomolar concentrations. Alexa 647 was slightly less satisfactory
due to a high fraction of molecules excited to the triplet state, which complicated fits at
short delay times. However, these two dyes proved to be a solid pair for FCCS work,
with little leakage between channels. The volume parameters we extracted correspond
well with values reported in practical guides to the method (Elson, 2011; Ferrand et al.,
2011).
CCR5 NABBs were characterized by FCS to determine sample homogeneity,
size, and, suitable storage conditions. Most samples were best fit to two-component
models, indicating some vesicle formation even in optimized preparations. Large
aggregates were observed rarely, however, and the resulting large deviations from mean
fluorescent intensities were easily identified so those experiments could be removed from
averages. Aggregates could be prevented for days after initial sample preparation by
supplementing NABBs with 50% glycerol and storing at -20°C. The inclusion of glycerol
prevents complete freezing, which may drive aggregation of NABBs. The faster diffusing
NABBs component in our experiments (500-700 µs) aligns well with previous FCS
reports of ~10 nm nanodiscs (Gao et al., 2011). We also demonstrate binding of a
labeled, conformationally sensitive antibody to CCR5 in NABBs, further indicating that
the samples include properly folded receptor. Future experiments with a range of
antibody and ligand concentrations will allow quantitative study of these binding
interactions in the presence and absence of small molecule drugs. Two color FCCS with
Alexa 488 and Alexa 647 should facilitate this work.
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Chapter Five: Chemical Crosslinking of Rhodopsin in
Native Membranes to Identify a Primary Dimerization
Interface*

5.1

Introduction

Like many other membrane receptors, GPCRs are known to form dimers and
higher-order oligomers in membranes. Functional trans-complementation assays, such as
one employing chimeric α2-adrenergic/M3 muscarinic receptors (Maggio et al., 1993),
have provided examples where intermolecular interactions are required for signaling.
Immunoprecipitation (Hebert et al., 1996) and bioluminescence resonance energy transfer
(Angers et al., 2000) have also demonstrated the presence of β2-adrenergic receptor
dimers. There are fewer reports describing the functional consequences of dimerization,
but they are known in some cases. GABA(B) receptor subtype heterodimerization is
required for trafficking to the plasma membrane (White et al., 1998). It has also been
shown that the chemokine receptors CXCR7 and CXCR4 form a heterodimer that
preferentially recruits β-arrestin rather than heterotrimeric G protein (Decaillot et al.,
2011). Still, both rhodopsin (Banerjee et al., 2008) and β2-adrenergic receptor (Whorton
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
*
Portions of this chapter have been published previously: Knepp AM, Periole X, Marrink
SJ, Sakmar TP and Huber T (2012) Rhodopsin Forms a Dimer with Cytoplasmic Helix 8
Contacts in Native Membranes. Biochemistry 51:1819-1821. Periole X, Knepp AM,
Sakmar TP, Marrink SJ and Huber T (2012) Structural Determinants of the
Supramolecular Organization of G Protein-Coupled Receptors in Bilayers. J Am Chem
Soc 134:10959-10965.
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et al., 2007) monomers can activate G proteins when segregated in membrane
nanoparticles. Another study showed that a 1:1 complex of rhodopsin:transducin resulted
in G protein activation at a rate near the diffusion limit (Ernst et al., 2007). This suggests
that a monomer is in fact the minimal functional unit for G protein signaling.
The concept of rhodopsin dimerization garnered increased attention upon
publication of atomic force microscopy (AFM) images of native rod outer segment
(ROS) disk membranes that showed rows of rhodopsin dimers (Fotiadis et al., 2003).
This provided perhaps the most striking demonstration yet of the visual system’s possible
supramolecular organization. The burst in GPCR structural biology over the past several
years has also contributed to the dimer debate. While the first crystal structure of
rhodopsin showed nonphysiological, antiparallel dimers (Palczewski et al., 2000), some
more recent structures, such as those of CXCR4 (Wu et al., 2010) and κ-opioid receptor
(Wu et al., 2012), showed physiologically plausible dimers. Despite these advances, the
precise interface(s) mediating receptor−receptor contacts remains controversial
(Palczewski, 2010). Spatial constraints from the AFM images were used to predict that
the primary rhodopsin dimer interface involved transmembrane (TM) helices 4 (H4) and
5 (H5) (Liang et al., 2003). However, two-dimensional (Schertler and Hargrave, 1995)
and three-dimensional (Ruprecht et al., 2004) densities obtained from electron
microscopy (EM) as well as X-ray data for packing of rhodopsin crystals (Salom et al.,
2006) show that dimer contacts involve TM H1 and cytoplasmic H8. Interestingly, the κopioid receptor crystal structure revealed dimers that almost exactly match those in the
3D EM densities. It is possible that solubilization conditions drive these dimers – indeed,
it has been shown that the choice of detergents greatly affects the oligomeric state of
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rhodopsin (Jastrzebska et al., 2006). However, a recent cross-linking study suggests the
H1/H8 interface exists for dopamine D2 receptors heterologously expressed at
physiological densities in membranes (Guo et al., 2008). The authors interpreted their
results in the context of an oligomeric model in which both the H4/H5 and H1/H8
symmetrical interfaces are simultaneously present.
We set out to demonstrate the possibility of the H1/H8 dimer in native disk
membranes by cross-linking the endogenous cysteines of rhodopsin and identifying the
site(s) involved. Here we go beyond previous studies of rhodopsin in that we identify
additional intermolecular cross-linking sites (Jastrzebska et al., 2004). Working with
receptors in the native membrane environment eliminates artifacts associated with
dimerization in detergent.
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5.2

Results

5.2.1 Chemical Crosslinking and Partial Proteolysis Analysis
Rhodopsin contains two primary reactive cysteines (positions 140 and 316), and
two additional cysteine residues in H8 (positions 322 and 323) may also be reactive
because of incomplete palmitoylation. Structural evidence suggests that the
Cys316−Cys316 distance in an H1/H8 interface would be 2−3 nm. (Ruprecht et al., 2004)
(Salom et al., 2006). In contrast, these side chains are on opposite faces and thus farther
from each other in an H4/H5 dimer arrangement. We hypothesized that a
Cys316−Cys316 cross-link using a reagent with a spacer length close to the predicted
distance would support the presence of the H1/H8−H1/H8 dimer.
Dark state ROS membranes were first cross-linked with two homobifunctional
bis-maleimide reagents containing polyethylene glycol (PEG) spacers of different lengths
(Figure 5-1A-B). The cross-linker:rhodopsin stoichiometry was controlled to optimize
cross-linking. If an overly large excess is used, the reactive cysteines saturate with the
reagent rather than cross-linking to a neighboring receptor. We found that a 5:1 excess of
cross-linker resulted in appreciable formation of dimers and higher-order oligomers that
could be observed on a gel. Addition of either BM(PEG)3 (2.1 nm, the sulfur−sulfur
distance in the extended conformation of the cross-link) or Bis-MAL-dPEG3 (3.1 nm)
reduced the amount of monomer present relative to a negative control.
To identify the region of the cross-link, we employed a partial proteolysis
procedure with thermolysin. Thermolysin cleaves rhodopsin at several C-terminal sites in
addition to a primary cut site in the third intracellular loop (Pober, 1982). The C-terminal
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Figure 5-1. Chemical cross-linking of rhodopsin in ROS disk membranes followed by
limited proteolysis and SDS−PAGE analysis with silver (A) and Coomassie (B) staining.
Samples were analyzed before (lanes 1−3) and after (lanes 4−6) thermolysin treatment
(proteolysis) in the absence of cross-linker (lanes 1 and 4), after cross-linking with
BM(PEG)3 (lanes 2 and 5), and after cross-linking with Bis-MAL-dPEG3 (lanes 3 and 6).
The cross-linkers are noncleavable homobifunctional cysteine-reactive reagents with
different spacer lengths. R′ results from cleavage of short C-terminal peptides; F1 is an
∼28 kDa N-terminal peptide, and F2 is an ∼12 kDa C-terminal peptide. The appearance
of the cross-linker-dependent band (F2)2 in lanes 5 and 6 of panel B demonstrates the
proximity of H8 in adjacent rhodopsin monomers in ROS, as described in the text. This
result is consistent with an H1/H8−H1/H8 dimer model.
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cuts result in a slightly shorter peptide, R′. Further proteolysis results in two predominant
fragments: an ∼28 kDa N-terminal peptide (F1) and an ~12 kDa C-terminal peptide (F2).
The F1 peptide contains Cys140, and the F2 peptide contains Cys316, Cys322, and
Cys323. Because these fragments are easily resolved on a gel, the region of the cysteine
cross-link can be determined by observing which of them oligomerize upon addition of
the bis-maleimide reagent. As shown in lane 4 of panels A and B of Figure 5-1, R′, F1,
and several forms of F2 (depending on the extent of C-terminal proteolysis) are the only
lower-molecular mass bands observed in a control sample. The F1 band stains relatively
poorly with Coomassie, likely because it is glycosylated, so it is clearer in the silverstained gel. On the other hand, the modified F2 bands are almost invisible with silver
staining, but prominent with Coomassie. Upon addition of either cross-linker (Figure 51B, lanes 5 and 6), the intensities of the F2 bands decrease and new bands appear near 20
kDa. These bands can correspond to only an F2 dimer, so we conclude that the H8
regions cross-link to each other and are thus in the proximity of each other in neighboring
receptors in ROS.
Next, we demonstrated the chemical specificity of the Cys cross-linking with two
methanethiosulfonate (MTS) reagents, MTS-O4-MTS (2.2 nm) and MTS-O5-MTS (2.6
nm). The MTS groups are extremely reactive, and cross-linking is observed after just 5
min (Figure 5-2). These reagents have an advantage in the fact that the covalent linkage
formed can be cleaved with a reducing agent. Treatment of cross-linked samples with
DTT before running a gel collapsed the higher-molecular mass bands back down to
primarily monomer, as observed in negative controls. This shows that the cross-linkerdependent bands are the result of thiol reactions and not nonspecific oligomerization.
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Figure 5-2. Chemical crosslinking of rhodopsin in ROS disc membranes with a cleavable
reagent. Samples were analyzed by SDS-PAGE with Coomassie staining in the absence
of crosslinker (lanes 1 and 2), in the presence of MTS-O4-MTS for 5 (lanes 3 and 4), 15
(lanes 5 and 6), and 60 min (lanes 7 and 8), and in the presence of MTS-O5-MTS for 5
(lanes 9 and 10), 15 (lanes 11 and 12), and 60 min (lanes 13 and 14). The even numbered
lanes were treated with DTT before running the gel. The reduction of crosslinked samples
to profiles resembling the negative control in lane 1 demonstrates the chemical specificity
of the crosslink.
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5.2.2 Liquid Chromatography-Mass Spectrometry Identification of Crosslinked
Peptides
We used liquid chromatography and mass spectrometry (LC−MS) to demonstrate
definitively the presence of a Cys316−Cys316 dimer cross-link. ROS samples were
solubilized, alkylated, and precipitated with trichloroacetic acid. The precipitate was then
digested with cyanogen bromide (CNBr), which cleaves after methionines at positions
309 and 317 to yield a small peptide that can be detected by LC−MS. The C-terminal
methionine is modified to a homoserine lactone as a result of the chemical cleavage, and
iodoacetamide treatment adds a carbamidomethyl group to Cys316 if it has not been
substituted with a cross-linker.
In cross-linked samples, the carbamidomethyl-modified 310−317 peptide was
identified first (Table 5-1) It appears as several isotopes, and its mass is accurate to
several parts per million with respect to theoretical monoisotopic masses. For Bis-MALdPEG3 samples, the cross-linked product is simply two 310−317 peptides plus the mass
of the reagent. This product appeared as a z = 4 ion (Figure 5-3A). For MTS peaks, we
identified the 310−317 peptide with carbamidomethyl and N-ethylmaleimide (NEM)
(resulting from reaction quenching) and then found the peptide substituted with a crosslinker. Monosubstituted MTS reagents have their second reactive group hydrolyzed to a
thiol, which can then be modified with NEM, and this peak was also present. Finally, the
cross-linked product was found, again with roughly parts per million accuracy (Figure 53B). Crucially, in samples treated with DTT prior to precipitation and digestion, the
peaks corresponding to the peptide substituted with the MTS cross-linker were not
observed. This additional control confirms the peak assignments. The mass spectrometry
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Table 5-1. Mass spectrometry peaks identified in analysis. The masses were calculated
by multiplying the peak m/z ratio by its assigned charge. The abbreviations are the
following. H: homoserine lactone (position 317 modified by CNBr treatment); C:
carbamidomethyl; B: Bis-MAL-dPEG3; N: N-ethylmaleimide; M: MTS- O5-MTS

Sample

Obs.
Mass

Theor.
mass

Error
(ppm)

Sequence ID

Ion

Bis-MAL-dPEG3

1050.508

1050.5029

4.85

310-316-H+C

M+2H

Bis-MAL-dPEG3

1051.512

1051.5029

8.65

310-316-H+C

M+2H+1

Bis-MAL-dPEG3

1052.514

1052.5029

10.55

310-316-H+C

M+2H+2

Bis-MAL-dPEG3

1053.514

1053.5029

10.54

310-316-H+C

M+2H+3

Bis-MAL-dPEG3

2510.216

2510.1954

8.21

2*(310-316-H)+B

M+4H+1

Bis-MAL-dPEG3

2511.212

2511.1954

6.61

2*(310-316-H)+B

M+4H+2

MTS-O5-MTS

1048.4836

1048.4872

3.43

310-316-H+C

M

MTS-O5-MTS

1118.5264

1118.5291

2.41

310-316-H+C+N

M+2H

MTS-O5-MTS

1119.5276

1119.5291

1.34

310-316-H+C+N

M+2H+1

MTS-O5-MTS

1120.5276

1120.5291

1.34

310-316-H+C+N

M+2H+2

MTS-O5-MTS

1121.529

1121.5291

0.09

310-316-H+C+N

M+2H+3

MTS-O5-MTS

1304.5999

1304.5801

15.18

310-316-H+M

M+H

MTS-O5-MTS

1305.6111

1305.5801

23.74

310-316-H+M

M+H+1

MTS-O5-MTS

1428.6198

1428.6199

0.07

310-316-H+M+N

M+H

MTS-O5-MTS

1429.6204

1429.6199

0.35

310-316-H+M+N

M+H+1

MTS-O5-MTS

1430.6214

1430.6199

1.05

310-316-H+M+N

M+H+2

MTS-O5-MTS

1431.6228

1431.6199

2.03

310-316-H+M+N

M+H+3

MTS-O5-MTS

2293.9846

2294.0223

16.43

2*(310-316-H)+M

M+1

MTS-O5-MTS

2294.9864

2295.0223

15.64

2*(310-316-H)+M

M+2

111

A

38.85

627.5540
z=4; M+1

m/z=627.5540

627.8033
z=4, M+2

O

O

Asn O

H
N

N
H

S

N
H

O

MW=2509.20

Phe O

H
N

N
H

Arg O
O

O
N

m/z=627.8033

0 10 20 30 40 50 60
Time (min)

627.5 627.6 627.7 627.8
m/z
O

39.17

0 10 20 30 40 50 60
Time (min)

Lys O

H
N

NH2

N
H

Gln O

Asn O

O

N
H

O

O

O

N
H

O

N
O

O
Asn

O
H2N

O

H
N

Lys

O

Gln
N
H

Phe

O

Arg

O

H
N

N
H

O

H
N

Asn

O

S
H
N

N
H

O
O

O

B
1146.9923
z=2; M+1
1147.4933
z=2; M+2

O

O

S

m/z=1146.9923

m/z=1147.4933

Asn O

H
N

N
H

42.90

0 10 20 30 40 50 60
Time (min)

0 10 20 30 40 50 60
Time (min)

1147.0 1147.2 1147.4 1147.6
m/z
O

42.90

N
H

O

N
H

Arg O

O

S

Phe O

H
N

N
H

Gln O

O

O

Lys O

H
N

NH2
Asn O

O

O

S

MW=2293.02
O

Asn

H2N
O

H
N

O

Lys

Gln
N
H

O

Arg

O

H
N

Phe

N
H

O

H
N

O

Asn

S
N
H

H
N
O

O
O

Figure 5-3. LC−MS analysis of Cys316−Cys316 cross-linked peptides. (A) Two
310−317 peptides cross-linked with Bis-MAL-dPEG3. The monoisotopic peaks are z = 4
ions. Liquid chromatograms integrated across the two MS peaks show that the species
elute at similar times. (B) Two 310−317 peptides cross-linked with MTS-O5-MTS. The
monoisotopic peaks are z = 2 ions and disappear from samples treated with DTT prior to
precipitation. Liquid chromatograms integrated across the MS peaks show that they elute
simultaneously.
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data conclusively demonstrate the existence of Cys316−Cys316 cross-links. It is notable
that this cross-link was only observed with the longer reagents (≥2.6 nm) but not with the
shorter reagents (≤2.2 nm), suggesting the distance between the side chains is less than
2.6 nm. However, the thermal mobility and other factors limit the accuracy of such
estimates.
The partial proteolysis and LC−MS data are complementary, highlighting the
importance of integrating diverse experimental data to identify cross-linking sites. The
gels in Figures 5-1 and 5-2 show extensive oligomerization, so more than one
dimerization interface must be relevant. The presence of the (F2)2 band demonstrates that
one of them involves the proximity of H8 regions on adjacent receptors. The LC−MS
experiments allow precise identification of the Cys316−Cys316 cross-linking site. The
results are especially convincing because the assigned MTS peaks disappear upon
addition of DTT, which cleaves the cross-link disulfide bond. Further, because the MTS
reagent hydrolyzes so quickly, it is likely that the cross-links result from prearranged
dimers and not from random collisions over extended periods of time. Interestingly, the
partial proteolysis data show H8 cross-links for all four reagents employed, but the
Cys316−Cys316 peaks were identified with only the two longer (Bis- MAL-dPEG3 and
MTS-O5-MTS) cross-linkers. It is possible that either Cys322 or Cys323 cross-links are
responsible for the gel shift with the shorter reagents. As with Cys140-containing
fragments, we were not able to identify these sites with our CNBr cleavage strategy.
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5.3

Discussion

Dimerization of transmembrane receptors is a common theme in signal
transduction (Heldin, 1995). GPCRs are no exception – a wealth of biochemical, cell
biology, and structural data suggest the presence of dimers (Bouvier, 2001). A
particularly compelling, though controversial, example is the report of AFM images of
rhodopsin dimers aligned into rows (Fotiadis et al., 2003). While earlier studies
demonstrated that rhodopsin could be cross-linked into dimers, the sites were not
identified (Jastrzebska et al., 2004). We set out to test the hypothesis that rhodopsin
forms dimers mediated by contacts in transmembrane helix 1 and cytoplasmic helix 8.
The cross-linking methods used were adapted from the work of earlier groups, in which
intramolecular cross-links were identified (Jacobsen et al., 2006; Suda et al., 2004). Here
we extend this work and report a Cys316-Cys316 intermolecular cross-link. The crosslink was identified by complementary partial proteolysis and LC-MS approaches and
with multiple cross-linkers, strongly supporting a H1/H8 dimer interface. Despite earlier
structural evidence suggesting the presence of this interface, its small protein burial
raised doubts about its relevance (Lodowski et al., 2007). Buried accessible surface area
is often used as a predictor of protein-protein interfaces in aqueous solution, but it seems
likely that additional forces, such as lipid-protein interactions, drive associations in
bilayers.
To further probe rhodopsin dimerization in membranes, coarse-grained molecular
dynamics (CGMD) studies of spontaneous rhodopsin assembly were conducted by our
collaborators (Periole et al., 2012). The second most frequently populated dimer cluster
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involved an H1/H8 interface similar to structures observed via X-ray crystallography and
EM (Figure 5-4). The Cys316−Cys316 side chain bead distance of this cluster (Figure 54C) was 2.3 nm (2.6 nm when fitting residues 310−322 of PDB entry 1U19). Notably, a
similar but less populated cluster (Figure 5-4D) showed a Cys316−Cys316 distance
closer to 1.9 nm (2.1 nm from the local fit of 1U19). It should be noted that the analysis
of the CGMD self-assembly simulations on a microsecond time scale does not predict
thermodynamic stability, and consequently, cluster populations do not reflect equilibrium
distributions. The two structures are spatiotemporally mutually exclusive, but it is
difficult to determine which of these arrangements is responsible for the cross-links
presented here. If the monomer−dimer exchange is slow on the time scale of the crosslinking experiment, the more stable interface may predominate and thereby exclude the
other possible orientation. On the other hand, if the dimers are more transient, then the
structure that brings Cys316 residues closer and thus increases the likelihood of crosslinking could account for the data presented.
Note that several distances between Cys316 residues in dimer structures are cited.
The Cys316-Cys316 distances generally refer to the distances measured between the Sγ
atoms in the corresponding residue in the two protomers. For the CGMD dimers, we
report distances of the side chain beads in the coarse grained model together with fits of
crystallographic structures to the coarse grained representations. The first distances
mentioned correspond to the distance between Cys316-Cys316 side chain beads in the
CGMD dimer clusters: 2.3 nm for the cluster in Figure 5-4C and 1.9 nm for the cluster in
Figure 5-4D. The dimer images in the figure panels were generated from a complete fit of
Cα 1-326 of PDB 1U19 to the CGMD beads. The Cys316-Cys316 distances of the Sγ
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Figure 5-4. Structural and CGMD analysis of H1/H8 dimer orientations. (A) Two
symmetry-related promoters from the crystal structure of photoactivated rhodopsin
[Protein Data Bank (PDB) entry 2I35]. (B) Crystal structure of rhodopsin (PDB entry
1GZM) fit to the electron density of a metarhodopsin I dimer observed in an EM image
(Ruprecht et al., 2004). (C and D) Crystal structure of rhodopsin (PDB entry 1U19) fit to
two distinct H1/H8−H1/H8 dimer clusters observed via CGMD analysis.
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atoms in these two dimer structures are 2.8 nm and 1.9 nm for 5.4C and 5.4D,
respectively. The local fits were generated in a similar manner, except that only Cα 310322 of PDB 1U19 was fit to the CGMD beads. This resulted in distances of 2.6 nm and
2.1 nm for Figure 5-4C and 5-4D, respectively, which are the distances noted in the
figure. Local fitting reduces the effects of distortions in other regions of the receptor that
otherwise might result in unsatisfactory fits.
The dimer interfaces observed in the CGMD studies were synthesized with
structural information obtained from the AFM images to build a supramolecular model of
the rod cell disc membrane (Figure 5-5). In this model, dimers interacting through the
H1/H8 interface are stabilized by lipid-lubricated contacts at a second interface involving
H4, H5, and H6. This arrangement was stable in further simulations over a µs time scale.
Despite studies that have demonstrated a single receptor is sufficient for full G protein
activation, the extremely high density of rhodopsin in disk membranes hints that a dimer
may be the primary structural unit that interacts with the heterotrimer. Recent EM images
of purified rhodopsin-transducin complexes display densities that favor modeling a
receptor dimer (Jastrzebska et al., 2011). It is tempting to speculate that the Gα subunit
may slide along the rows of dimers in a one-dimensional search for activated receptors.
This could explain the very fast temporal response of the system, which exceeds that
predicted by free diffusion (Dell'Orco and Schmidt, 2008). In this case, Gβγ would ride in
the bilayer slot between rows.
Taken together, the biochemical cross-linking experiments strongly suggest a
rhodopsin dimer interface mediated by H1/H8 contacts. This structure has been suggested
by previous cross-linking, EM, and crystallography data. Encouragingly, this interface
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was also observed in CGMD simulations of rhodopsin monomers in a bilayer. Because
cross-linking caused the formation of oligomers, a second interface, perhaps involving
H4/H5 contacts, must also be present. The high degree of homology in class A GPCRs
suggests that the results reported here might be relevant for other receptors that are
known to oligomerize.
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Figure 5-5. Model of the rows-of-dimers organization of rhodopsin molecules after a 16µs CGMD simulation. The starting conformation was built according to the cell
dimensions determined from AFM images of rhodopsin in disk membranes prepared
from mouse retinas (Fotiadis et al., 2003; Liang et al., 2003). The lipid molecules are
shown as cyan dots placed at the location of the phosphate groups. Rhodopsins are shown
in deep red using cylinders for the helices and gray tubes for the backbone trace. The
large orange spheres are centered on Thr242 to show the H6 protrusion. The monoclinic
unit cell (γ = 85°) is outlined by a black box; the view is from the cytoplasmic surface.
Figure taken from (Periole et al., 2012).
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Chapter Six: Future Perspectives

The present is an exciting time in GPCR research. Advances in structural biology,
biophysical methods, and chemical biology have energized the field and enabled
unprecedented insights into the structure-function relationships of these remarkably
important receptors. As described throughout this thesis, much work remains to be done
to unite high-resolution structural information with the observed complex signaling
phenomena. The technologies and findings herein lend themselves to several threads of
ongoing work that support these efforts.
The rate of new crystal structures has rapidly increased in the past several years.
Nonetheless, many therapeutically important receptors have yet to yield to crystallization,
including CCR5. Since the role of CCR5 in HIV infection was discovered, it has attracted
a tremendous amount of attention, and a number of small molecules and biologics have
been developed with the aim of blocking viral entry. Though extensive mutagenesis
(Maeda et al., 2006; Seibert et al., 2006) and more recent targeted photocrosslinking
(Grunbeck et al., 2012) studies have identified the putative binding pockets of some of
these drugs, a high-resolution structure would provide new insights that inform existing
therapies and perhaps facilitate development of new ones. The HTRF analytical assay has
enabled identification of exceptionally stable CCR5 mutants (StaRs), a key step toward
crystallization. Intriguingly, though these mutants were shown to be G protein-signalingdead, they are capable of mediating viral entry. This suggests that a high-resolution
structure of one of the StaRs would display an infection-relevant conformation of the
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extracellular loops. Though co-crystallization with viral envelope glycoproteins may not
be feasible, a combination of docking models and molecular dynamics simulations could
shed light on the structural basis of co-receptor activity. Additionally, because CCR5
plays a central role in the immune response, antagonists developed with the initial aim of
preventing HIV infection may also find a role in different indications such as rheumatoid
arthritis (Horuk, 2009). Detailed structural information of this receptor would advance
this ongoing progress. Moreover, the HTRF immunosandwich assay represents a useful
new tool for GPCRs and other relatively intractable membrane proteins. Though the
formulation developed in this work used a conformationally sensitive antibody, even
antibodies to linear epitopes may be sensitive to receptor aggregation upon heat
treatment. If this is indeed the case, the approach would be seemingly generalizable to
any target of interest that can be appropriately tagged.
The unique properties of the stabilized CCR5 mutants make them interesting
candidates for further studies aiming to tease out complicated allosteric behavior.
Competition experiments with wild type receptor strongly suggested that small molecule
antagonists promote unique conformations (Figure 3-13). Though these data are
compelling, the FRET-based experiment cannot distinguish between two plausible
explanations for why the signals are lower than unliganded receptor. The small molecules
could shift the antibody-receptor equilibrium, resulting in fewer receptors binding both
labeled antibodies. Alternatively, the molecules could induce subtle changes in loop
conformation that cause the antibody to bind in a different orientation, which would
change the distance between donor and acceptor fluorophores. Single molecule
fluorescence experiments are capable of ascertaining the correct explanation. Chapter 4
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describes a method to incorporate CCR5 into membrane nanoparticles called NABBs,
which are useful platforms for single molecule studies. The resultant structures are
thermally stable, and the membrane bilayer environment should support folded,
functional receptors.
A capture method and TIRF system, in conjunction with site-specific labeling
methods, enable long timescale observations of receptors. A capturing surface comprising
several layers has already been developed in the Sakmar Lab. The glass surface of a 384well plate is first silanated to increase its binding capacity. Sequential incubations and
washes are then carried out with biotinylated BSA, NeutrAvidin, and biotinylated 1D4
antibody. Remaining biotin binding sites are saturated with biotin prior to addition of
fluorescent samples. With labeled CCR5 and labeled 2D7, one could measure the number
of receptors bound and not bound to antibodies through fluorescence colocalization. The
effects of the small molecules on equilibrium distributions could be tested by adding
them at a range of concentrations. On- and off-rates are also accessible by building
histograms of the time receptors spend in bound and unbound states before dissociation
and association, respectively. The theory and practice of these types of experiments has
been well-described (Lakowicz, 2006), and the fluorescently labeled oligonucleotides
described in Chapter 4 will serve as useful standards.
With labeled GPCRs, chemokines and G protein subunits, single molecule
fluorescence can be applied to address some fundamental questions. Examples include:
whether one or two receptors bind the heterotrimer, the precise sequence of signalosome
assembly and disassembly, and whether G proteins precouple to receptors (Nobles et al.,
2005; Oldham and Hamm, 2007). The stabilized receptor mutants may prove to be
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especially interesting tools here – though they do not appear to bind RANTES with
measurable affinity, they may bind other chemokines or couple to G proteins in an
unproductive manner. Recombinant chemokine analogues with unique antiviral and
signaling properties could also be tested (Gaertner et al., 2008). Because the experimental
platforms have been designed to handle very small amounts of sample, the numerous
combinatorial possibilities can be explored without becoming prohibitively laborious
and/or expensive.
FCS represents a valuable complementary method to TIRF. While not strictly a
single molecule technique, samples are observed in solution so any artifacts associated
with surface immobilization are bypassed. Applying two color FCCS to these problems
enables many of the same binding events to be monitored quantitatively. This method is
not merely confirmatory, however. FCCS may be a superior approach for bringing these
studies in vivo, as previous work has demonstrated its potential for studying interactions
within signaling networks (Slaughter et al., 2007). The development of standards and
analysis methods described in Chapter 4 should facilitate work along these lines. Like
TIRF, FCS is a very sensitive technique that requires small sample quantities.
The functional consequences of GPCR dimerization might also be accessible
through these methods. NABBs are a particularly attractive system for this application
because dimers can be isolated. Though earlier work showed that GPCR monomers
efficiently activate G proteins, it is possible that a dimerization results in preferential
recruitment of certain cytoplasmic proteins over others. To use CXCR4-CXCR7
heterodimerization as an example (Decaillot et al., 2011), one could label both receptors
and look for differences in binding to G protein subunits between monomers and
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colocalized receptors.
A variety of data will be needed to advance our understanding of the structural
basis of GPCR dimerization. Crystallography serves an integral role, especially if
physiologically relevant structures can be trapped. This might be accomplished by
strategically crosslinking receptors prior to purification, or by assessing the effect of
detergents and lipids on the oligomeric state of the receptor. Chemical crosslinking
experiments combined with methods to identify the site(s) should be applied to receptors
other than rhodopsin, especially in cases where dimers have been suggested to play a
functional role. Because heterologous expression systems will be necessary for other
receptors, maintaining a physiological receptor density will be crucial to the obtainment
of meaningful results (Guo et al., 2008). Finally, a combination of computational
approaches (Periole et al., 2012) and structural methods such as AFM and cryo-EM will
be needed to construct supramolecular models of GPCRs oligomers and other binding
partners. Though extremely high receptor densities make the visual system a special case,
it is possible that GPCRs form higher-order structures in plasma membrane regions with
certain lipid compositions, resulting in a similar improvement of temporal response to a
stimulus.
In sum, GPCRs will continue to be one of the more challenging and important
research foci in human biology. Their central role in physiology and therapeutics
mandate attention, and their complex signaling behavior ensures there will be no shortage
of open questions to pursue. Though these receptors present considerable obstacles, the
many recent technical advances have made the most interesting problems more tractable
than ever before.
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